WO2005005417A1 - Pyrrole-2, 5-dione derivatives as liver x receptor modulators - Google Patents

Pyrrole-2, 5-dione derivatives as liver x receptor modulators Download PDF

Info

Publication number
WO2005005417A1
WO2005005417A1 PCT/SE2004/001114 SE2004001114W WO2005005417A1 WO 2005005417 A1 WO2005005417 A1 WO 2005005417A1 SE 2004001114 W SE2004001114 W SE 2004001114W WO 2005005417 A1 WO2005005417 A1 WO 2005005417A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
treatment
amino
dione
pyrrole
Prior art date
Application number
PCT/SE2004/001114
Other languages
French (fr)
Inventor
Jonas BOSTRÖM
Kay Brickmann
Patrik Holm
Pernilla Sandberg
Marianne Swanson
Christer Westerlund
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA06000414A priority Critical patent/MXPA06000414A/en
Priority to US10/564,235 priority patent/US7432288B2/en
Priority to EP04749150A priority patent/EP1646626B1/en
Priority to AU2004255999A priority patent/AU2004255999B2/en
Priority to JP2006520138A priority patent/JP2007521312A/en
Priority to CA002532056A priority patent/CA2532056A1/en
Priority to DE602004014773T priority patent/DE602004014773D1/en
Priority to BRPI0412472-3A priority patent/BRPI0412472A/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to UAA200600272A priority patent/UA82109C2/en
Publication of WO2005005417A1 publication Critical patent/WO2005005417A1/en
Priority to IL172760A priority patent/IL172760A0/en
Priority to NO20060081A priority patent/NO20060081L/en
Priority to IS8293A priority patent/IS8293A/en
Priority to HK06108803.4A priority patent/HK1088320A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to certain novel 1 -(substituted alkyl)- 3 amino- 4 phenyl- 1H- pyrrole-2,5-dione derivatives, to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ⁇ (NR1 ⁇ 3) and/or ⁇ (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
  • LXR Liver X Receptor
  • NR1 ⁇ 3 NR1 ⁇ 3
  • NR1H2 ⁇
  • cardiovascular diseases such as atherosclerosis
  • inflammatory diseases such as Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of
  • CND cardiovascular disease
  • LXR and ⁇ use oxysterols as natural ligands. They appear to act as cholesterol sensors with target genes that are required for cholesterol efflux from macrophages, like ATP binding casette transporter Al (ABCA1) and apoE, as well as gene products, like cholesterol ester transferase protein (CETP) and phospholipid transport protein (PLTP), that are required for the function of high density lipoprotein (HDL) in the reverse cholesterol transport.
  • LXR upregulates lipoprotein lipase in liver and macrophages, a function that may stimulate fatty acid uptake and very low density lipoprotein (NLDL) remodeling.
  • LXR ligands seem to stimulate the hepatobiliary secretion of cholesterol, a pathway controlled by the ABCG5 and ABCG8.
  • the same cholesterol transporters appear to reduce cholesterol absorption in enterocytes, therefore influencing total body cholesterol balance.
  • LXR ligands GW3965 (Glaxo) and T-0901317 (Tularik) were reported to increase glucose tolerance in fat fed obese mouse, which was interpreted to result from reduced hepatic gluconeogenesis and increased glucose uptake in adipocytes Lafitte BA et al. (Proc ⁇ atl Acad Sci U S A. 2003 Apr 29; 100(9): 5419-24). Activation of LXR's improves glucose tolerance through coordinated regulation of glucose metabolism in liver and adipose tissue.
  • WOOO/21927 discloses pyrrole-2,5-diones, which are GSK-3 inhibitors and claimed to be useful in the treatment of dementias such as Alzheimer's disease, manic depression and diabetes. There is no suggestion that these compounds have activity as LXR modulators.
  • LXR modulator means a small molecule that modulates the biological activities of LXR ⁇ and/or LXR ⁇ . More specifically, such an LXR modulator either enhances or inhibits the biological activities of LXR. If such a modulator partially or completely enhances the biological activities of LXR, it is a partial or full LXR agonist, respectively. It is the object of the present invention to provide LXR modulators. Another object of this invention is to provide LXR modulator compounds being LXR agonists.
  • R 1 is selected from phenyl(l-4C)alkyl wherein the phenyl is substituted by (1- 4C)alkoxycarbonyl or a group of formula NR a R b in which R a and R b independently represent H or (l-4C)alkyl; heteroaryl(l-4C)alkyl wherein the heteroaryl optionally is substituted by (1-4C) alkyl or a group of formula NR a R b in which R a and R b independently represent H or (l-4C)alkyl; or a (l-4C)alkyl group which is substituted by one or more of the following: fluoro, (l-4C)alkoxycarbonyl, (l-3C)alkylthio or (l-3C)alkoxy optionally substituted by one or more fluoro; R 2 is phenyl; R 3 is selected from phenyl, indolyl or benzofuranyl each optionally substituted by one or more of the following: (l
  • heteroaryl means pyridyl, furyl or isoxazolyl each of which is optionally substituted by one or more of the following: (l-4C)alkyl or a group of formula NR a R b in which R a and R b independently represent H or (l-4C)alkyl.
  • R 1 is selected from 2-mefhoxyethyl, 2-methylthioethyl, 2,2,2-trifluoroethyl, 3- methoxypropyl, 3,3,3-trifluoropropyl, ethoxycarbonylmethyl, 4-NN-dimethylaminobenzyl, 4- methoxycarbonylbenzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 6-amino- 3-pyridylmethyl, 3-furylmethyl or (5-methylisoxazol-3yl)methyl.
  • R 3 is selected from phenyl, 4-methoxyphenyl, 4-methylthiophenyl, 4-morpholinophenyl, 4-acetylaminophenyl, 4-trifluoromethoxyphenyl, 4-difluoromethoxyphenyl or 2-acetyl-5- benzofuranyl.
  • R 1 is selected from 2-methoxyethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 3- methoxypropyl, ethoxycarbonylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4- pyridylmethyl, 6-amino-3-pyridylmethyl or (5-methylisoxazol-3yl)methyl;
  • R 2 is phenyl;
  • R is selected from phenyl, 4-methoxyphenyl, 4-acetylaminophenyl, 4- difluoromethoxyphenyl or 4-morpholinophenyl.
  • R 1 is selected from 2-methoxyethyl, 6-amino-3-pyridylmethyl, 3-pyridylmethyl or 2,2,2- trifluoroethyl
  • R 2 is phenyl
  • R is selected from 4-methoxyphenyl, 4-difluoromethoxyphenyl, 4- trifluoromethoxyphenyl or 4-morpholinophenyl.
  • R 1 is selected from 2,2,2-trifluoroethyl, 3-furylmethyl, 6-amino-3-pyridylmethyl or 3- pyridylmethyl;
  • R 2 is phenyl;
  • R 3 is selected from 4-methoxyphenyl , 4-difluoromethoxyphenyl, 4-morpholinophenyl or 2-acetyl-5 -benzofuranyl .
  • E 1 is selected from 6-amino-3 ⁇ pyridylm ⁇ thyl or 2-methoxyethyl;
  • R 2 is phenyl; and
  • R 3 is selected from 4-morpholinophenyl, 4-trifluoromethoxyphenyl or 4- difluoromethoxyphenyl.
  • R 1 is selected from 6-amino-3-pyridylmethyl, 3-furylmethyl, 3-pyridylmethyl, 2,2,2- trifluoroethyl or 2-methoxyethyl;
  • R is phenyl;
  • R 3 is selected from 4-morpholinophenyl, 4-methoxyphenyl, 4-trifluoromethoxyphenyl, 4- difluoromethoxyphenyl or 2-acetyl-5-benzofuranyl.
  • the compounds of formula I have activity as medicaments.
  • the compounds of formula I are LXR agonists.
  • Specific compounds of the invention are one or more of the following: 1 -(2-Methoxyethyl)-3-[(4-methoxyphenyl)amino]-4-phenyl- lH-pyrrole-2,5-dione
  • Certain compounds of the present invention may exist as tautomers. It is to be understood that the present invention encompasses all such tautomers.
  • the compounds of the invention may be prepared as outlined below. However, the invention is not limited to these methods.
  • the compounds may also be prepared as described for structurally related compounds in the prior art.
  • the reactions can be carried out according to standard procedures or as described in the experimental section.
  • R 1 is as previously defined in the presence of a dialkyl azodicarboxylate, for example diethyl azodicarboxylate, and a phosphine, for example triphenylphosphine, optionally in the presence of an inert organic liquid for example an ether e.g. tetrahydrofuran at a temperature in the range of 0°C to 200°C.
  • a dialkyl azodicarboxylate for example diethyl azodicarboxylate
  • a phosphine for example triphenylphosphine
  • an inert organic liquid for example an ether e.g. tetrahydrofuran at a temperature in the range of 0°C to 200°C.
  • R 1 and R 2 are as previously defined and Y is a leaving group for example halo e.g. CI, Br or I with a compound of formula V R 3 NH 2 V in which R is as previously defined optionally in the presence of an inert organic liquid for example dimethylformamide optionally in the presence of a base for example potassium carbonate at a temperature in the range of 0°C to 250°C.
  • Y is a leaving group for example halo e.g. CI, Br or I with a compound of formula V R 3 NH 2 V in which R is as previously defined optionally in the presence of an inert organic liquid for example dimethylformamide optionally in the presence of a base for example potassium carbonate at a temperature in the range of 0°C to 250°C.
  • R2 is as previously defined and Y is a leaving group for example halo eg CI, Br or I with a compound of formula N R 3 ⁇ H 2 V in which R is as previously defined optionally in the presence of an inert organic liquid for example dimethylformamide and optionally in the presence of a base for example triethylamine at a temperature in the range of 0°C to 250°C.
  • R is as previously defined and Y is a leaving group for example halo eg CI, Br or I with a compound of formula NLU R 1 ⁇ H 2 Nm in which R 1 is as previously defined optionally in the presence of an organic liquid, for example glacial acetic acid at a temperature in the range of 0°C to 200°C.
  • Y is a leaving group for example halo eg CI, Br or I with a compound of formula NLU R 1 ⁇ H 2 Nm in which R 1 is as previously defined optionally in the presence of an organic liquid, for example glacial acetic acid at a temperature in the range of 0°C to 200°C.
  • Compounds of formula IN may also be prepared by reacting a compound of formula NI with a compound of formula XI R*L XI in which R is as as previously defined and L is a leaving group for example halo eg CI, Br or I in the presence of an inert organic liquid for example dimethylformamide and optionally in the presence of a base for example potassium carbonate at a temperature in the range of -78°C to 200°C.
  • R is as previously defined with a halogenating agent for example oxalyl chloride optionally in the presence of an inert organic liquid for example dichloromethane and optionally in the presence of a catalytic amount of dimethylformamide at a temperature in the range of 0°C to 200°C.
  • a halogenating agent for example oxalyl chloride
  • an inert organic liquid for example dichloromethane
  • a catalytic amount of dimethylformamide at a temperature in the range of 0°C to 200°C.
  • R is as previously defined with a halogenating agent for example thionyl chloride optionally in the presence of an inert organic liquid for example dichloromethane and optionally in the presence of a base for example pyridine at a temperature in the range of O°C to 200°C.
  • a halogenating agent for example thionyl chloride
  • an inert organic liquid for example dichloromethane
  • a base for example pyridine
  • the compounds of the invention may be isolated from their reaction mixtures using conventional techniques.
  • inert organic liquid refers to a solvent which does not react with the starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
  • the compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in a pharmaceutically acceptable dosage form.
  • the compositions may be administered at varying doses.
  • Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.0001-100 mg/kg body weight, preferably 0.01-10 mg kg body weight.
  • Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.7 mg to 700 mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg and 250 mg.
  • a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
  • the compounds of formula I are useful for normalization of cholesterol homeostasis, decreasing intestinal cholesterol absorption, improving reverse cholesterol transport, improving HDL functionality, increasing HDL-cholesterol levels, decreasing LDL- cholesterol levels, decreasing cholesterol content of apoB -containing lipoproteins, stimulating cholesterol efflux from vascular cells and/or decreasing the inflammatory response of vascular cells. As a consequence of these properties the compounds of formula I are expected to have anti-atherosclerotic effects.
  • the compounds of formula I are useful in the prevention or treatment of cardiovascular disease in a mammal, particularly a human.
  • the compounds of formula I are useful in the prevention or treatment of atherosclerosis in a mammal, particularly a human.
  • Cardiovascular disease includes but is not limited to conditions associated with atherosclerosis, arteriosclerosis, hypercholesterolemia, and other kinds of dyslipidemia that increase the risk for cardiovascular disease.
  • the compounds of formula I are useful in the treatment or prevention of cardiovascular disease, especially those involving atherosclerosis and hypercholesterolemia.
  • the compounds of formula I also serve to prevent lipid accumulation in, or remove lipids from, tissue deposits such as atherosclerotic plaques or xanthomas in a patient with atherosclerotic disease manifest by clinical signs such as angina, claudication, Sons, one that has suffered a mycardial infarction or transient ischemic attack, or one diagnosed by angiography, sonography or MRI.
  • the compounds of formula I also serve to prevent or reduce the risk of developing atherosclerosis, as well as for halting or slowing the progression of atherosclerotic disease once it has become clinically evident, comprising the administration of a prophylactically or therapeutically effective amount, as appropriate, of a compound of formula I to a mammal, including a human, who is at risk of developing atherosclerosis or who already has atherosclerotic disease.
  • Atherosclerosis encompasses vascular diseases and conditions that are recognized and understood by physicians practicing in the relevant fields of medicine.
  • Atherosclerotic cardiovascular disease including restenosis following revascularization procedures coronary heart disease (also known as coronary artery disease or ischemic heart disease), cerebrovascular disease including multi-infarct dementia, and peripheral vessel disease including erectile dysfunction are all clinical manifestations of atherosclerosis and are therefore encompassed by the terms "atherosclerosis” and "atherosclerotic disease”.
  • the present compounds of formula I are also useful for the prophylaxis and/or treatment of clinical conditions associated with atherosclerosis such as inherent or induced hypercholesterolemia as well as inherent or induced reduced sensitivity to insulin (insulin resistance syndrome also known as metabolic syndrome) and associated metabolic disorders.
  • clinical conditions will include, but will not be limited to, general obesity, abdominal obesity, arterial hypertension, hyperinsulinaemia, hyperglycaemia, type 2 diabetes and the dyslipidaemia characteristically appearing with insulin resistance.
  • This dyslipidaemia also known as the atherogenic lipoprotein profile, is characterised by moderately elevated non-esterified fatty acids, elevated NLDL triglyceride rich particles, high ApoB levels, low HDL levels associated with low apoAI levels in the presence of small, dense, LDL particles, phenotype B.
  • the compounds of formula I are expected to be useful in treating patients with combined or mixed hyperlipidemias and dyslipidemias, especially low HDL levels with or without other manifestations of the metabolic syndrome.
  • Treatment with the compounds of formula I are expected to lower the cardiovascular morbidity and mortality associated with atherosclerosis due to their antidyslipidaemic as well as antiinflammatory properties.
  • the cardiovascular disease conditions include macro- angiopathies of various internal organs causing myocardial infarction, congestive heart failure, cerebrovascular disease and peripheral arterial insufficiency of the lower extremities.
  • the insulin sensitizing effect of the compounds of formula I is also expected to prevent or delay the development of type 2 diabetes from the metabolic syndrome and diabetes of pregnancy. Therefore the development of long-term complications associated with chronic hyperglycaemia in diabetes mellitus such as the micro-angiopathies causing renal disease, retinal damage and peripheral vascular disease of the lower limbs are expected to be delayed.
  • the compounds of formula I may also be useful for the prevention or treatment of inflammation and neurodegenerative diseases or neurological disorders. Accordingly, this invention also provides a method for preventing or treating inflammation in the CNS and a method for preventing or treating neurodegenerative diseases or disorders characterized by neuron degeneration, neuron injury or impaired plasticity or inflammation in the CNS.
  • the neurodegenerative diseases or conditions characterized by neuron degeneration and inflammation will include but will not be limited to stroke, Alzheimer's disease, fronto- temporal dementias (taupathies), peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis.
  • the compounds of formula I are useful in preventing or treating inflammatory conditions or diseases.
  • diseases or conditions will include but will not be limited to atherosclerotic diseases such as angina pectoris and myocardial infarction as well as inflammatory bowel diseases or conditions such as Crohn's disease, ulcerative colitis and distal proctitis.
  • Compounds of formula I may also be used in other inflammatory conditions of the lung including asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease and pneumonia bronchitis.
  • the compounds of formula I may be useful in treatment of various conditions outside the cardiovascular system whether or not associated with insulin resistance, like polycystic ovarian syndrome, obesity and cancer.
  • the present invention provides a method of treating and/or preventing dyslipidemias, the insulin resistance syndrome and/or metabolic disorders (as defined above) comprising the administration of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing type 2 diabetes comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing cardiovascular disease comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing atherosclerosis comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing hypercholesterolemia comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing conditions associated with a need for improving reverse cholesterol transport comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing conditions associated with a need for decreasing intestinal cholesterol absorption comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing conditions associated with a need for increasing HDL-cholesterol levels comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing conditions associated with a need for decreasing LDL-cholesterol levels comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing inflammatory conditions comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing Alzheimer's disease comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing arteriosclerosis comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing conditions associated with a need for improving HDL function comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides a method of treating and/or preventing hyperlipidemic conditions comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
  • the present invention provides the use of a compound of formula I as a medicament.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prohylaxis of dyslipidemic conditions.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prohylaxis of insulin resistance and/or metabolic disorders. In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of cardiovascular disease.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of atherosclerosis.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of hypercholesterolemia.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for improving reverse cholesterol transport.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for decreasing intestinal cholesterol absorption.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for increasing HDL-cholesterol levels.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for decreasing LDL-cholesterol levels.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of inflammatory conditions. In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of Alzheimer's disease.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of arteriosclerosis.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of type 2 diabetes.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for improving HDL function.
  • the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidemic conditions.
  • the compounds of the invention may be combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes, inflammation and obesity.
  • the compounds of the invention may be combined with another therapeutic agent that decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol.
  • the compounds of the invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.
  • the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with cholesterol biosynthesis inhibitors, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • Suitable cholesterol biosynthesis inhibitors include HMG CoA reductase inhibitors, squalene synthesis inhibitors and squalene epoxidase inhibitors.
  • a suitable squalene synthesis inhibitor is squalestatin 1 and a suitable squalene epoxidase inhibitor is NB-598.
  • the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administrated in association with an HMG CoA reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • an HMG CoA reductase inhibitor or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are statins well known in the art.
  • statins are selected from the group consisting of atorvastatin, fluvastatin, pitavastatin, lovastatin, mevastatin, nicostatin, nivastatin, pravastatin and simvastatin, or a pharmaceutically acceptable salt, especially sodium or calcium, solvate, solvate of such a salt or a prodrug thereof.
  • a particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a more particular statin is atorvastatin calcium salt.
  • a particularly preferred statin is, however, rosuvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a preferable particular statin is rosuvastatin calcium salt.
  • cholesterol biosynthesis inhibitors also includes chemical modifications of the HMG CoA reductase inhibitors, squalene synthesis inhibitors and squalene epoxidase inhibitors, such as esters, prodrugs and metabolites, whether active or inactive.
  • the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with an inhibitor of the ileal bile acid transport system (IB AT inhibitor), or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • IB AT inhibitor ileal bile acid transport system
  • Suitable compounds possessing IBAT inhibitory activity have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/07449, WO 98/03818, WO 98/38182, WO 99/32478, WO 99/35135, WO 98/40375, WO 99/35153, WO
  • IBAT inhibitors suitable for use in the present invention are benzothiazepines, and the compounds described in the claims, particularly claim 1, of WO 00/01687, WO 96/08484 and WO 97/33882 are incorporated herein by reference.
  • Other suitable classes of LB AT inhibitors are the 1,2-benzothiazepines, 1,4-benzothiazepines and 1,5-benzothiazepines.
  • a further suitable class of IBAT inhibitors is the 1,2,5- benzothiadiazepines .
  • IBAT inhibitory activity is (3R,5R)-3-butyl- 3-ethyl- 1 , 1 -dioxido-5-phenyl-2,3 ,4,5-tetrahydro- 1 ,4-benzothiazepin-8-yl ⁇ -D- glucopyranosiduronic acid (EP 864 582).
  • a further suitable compound possessing IBAT inhibitory activity is S-8921 (EP 597 107).
  • the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with a cholesterol absorption antagonist , or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example azetidinones such as ezetrol (zetia, ezetimibe) and those described in US 5,767,115 which are incorporated herein by reference.
  • azetidinones such as ezetrol (zetia, ezetimibe) and those described in US 5,767,115 which are incorporated herein by reference.
  • Suitable compounds possessing cholesterol absorption antagonist activity have been described, see for instance the compounds described in WO 02/50027, WO 02/66464, WO 04/005247, WO 04/000803, WO 04/000804 and WO 04/000805 which are incorporated herein by reference.
  • the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with a bile acid sequestrant or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • Suitable bile acid sequestrants include cholestyramine, cholestipol and cosevelam hydrochloride.
  • the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with a peroxisome proliferator-activated receptor (PPAR) modulating agent.
  • PPAR modulating agents include but are not limited to a PPAR alpha and/or gamma and/or delta agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • Suitable PPAR alpha and/or gamma and/or delta agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art.
  • a PPAR alpha and/or gamma and/or delta agonist refers to muraglitazar (BMS 298585), rivoglitazone (CS-011), netoglitazone (MCC-555), balaglitazone (DRF-2593, NN-2344), clofibrate, fenofibrate, bezafibrate, gemfibrozil , ciprofibrate, pioglitazone, rosiglitazone, ANE-0847, ANE-8134, CLX-0921, DRF-10945, DRF-4832, LY-518674, LY-818, LY-929, 641597, GW-590735, GW-677954, GW-501516, MBX-102, O ⁇ O-5129, KRP-101, R-483 (BM131258), TAK- 559 or TAK-654.
  • BMS 298585 muraglitazar
  • CS-011
  • a PPAR alpha and/or gamma and/or delta agonist refers to tesaglitazar ((S)-2-ethoxy-3-[4-(2- ⁇ 4-methanesulphonyl- oxyphenyl ⁇ ethoxy) ⁇ henyl]propanoic acid) and pharmaceutically acceptable salts thereof.
  • the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with a pyruvate dehydrogenase kinase (PDK) inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, or modulators of nuclear receptors such as retenoid X receptor (RXR), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • PDK pyruvate dehydrogenase kinase
  • RXR retenoid X receptor
  • the compound of formula I may be administered in association with a cholesteryl ester transfer protein (CETP) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example those referenced and described in WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference.
  • CETP cholesteryl ester transfer protein
  • the compound of formula I may be administered in association with a microsomal transfer protein (MTP) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example implipatide and those described in WO 03/004020, WO 03/002533, WO 02/083658 and WO 00/242291, and the contents of these patent applications are incorporated herein by reference, or those described in Science, 282, 751-54, 1998 which are incorporated herein by reference.
  • MTP microsomal transfer protein
  • the compound of formula I may be administered in association with a nicotinic acid derivative, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, including slow release and combination products, for example, nicotinic acid (niacin), acipimox, nicofuranose, NIASPAN® and niceritrol.
  • nicotinic acid niacin
  • acipimox nicofuranose
  • NIASPAN® niceritrol
  • the compound of formula I may be administered in association with a acyl coenzymA: cholesterol O-acyltransferase (ACAT) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example CS-505, eflucimibe (F-12511) and SMP-797.
  • ACAT cholesterol O-acyltransferase
  • the compound of formula I, association with modulators of nuclear receptors such as farnesoid or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in X receptor (FXR), or pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • FXR X receptor
  • the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with a phytosterol compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example stands.
  • the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with other therapies for the treatment of metabolic syndrome or type 2 diabetes and its associated complications, these include biguanide drugs, for example metformin, phenformin and buformin, insulin (synthetic insulin analogues, amylin) and oral antihyperglycemics (these are divided into prandial glucose regulators and alpha- glucosidase inhibitors).
  • An example of an alpha-glucosidase inhibitor is acarbose or voglibose or miglitol.
  • An example of a prandial glucose regulator is repaglinide or nateglinide.
  • the compound of formula I may be administered in association with a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, gliquidone, chloropropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolcylamide and tolazamide.
  • a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, gliquidone, chloropropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole,
  • the sulfonylurea is glimepiride or glibenclamide (glyburide). More preferably the sulfonylurea is glimepiride. Therefore the present invention includes administration of a compound of the present invention in conjunction with one, two or more existing therapies described in this paragraph.
  • the doses of the other existing therapies for the treatment of type 2 diabetes and its associated complications will be those known in the art and approved for use by regulatory bodies for example the FDA and may be found in the Orange Book published by the FDA. Alternatively smaller doses may be used as a result of the benefits derived from the combination.
  • the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with an antihypertensive compound for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha andrenergic blocker, a beta andrenergic blocker, a mixed alpha/beta andrenergic blocker, an andrenergic stimulant, calcium channel blocker, an AT-1 blocker, a saluretic, a diuretic or a vasodilator, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • an antihypertensive compound for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha andrenergic blocker, a beta andrenergic blocker, a mixed alpha/beta andrene
  • Particular ACE inhibitors or pharmaceutically acceptable salts, solvates, solvate of such salts or prodrugs thereof, including active metabolites, which can be used in combination with a compound of formula I include but are not limited to, the following compounds: alacepril, alatriopril, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril- glutathione, ceranopril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fos
  • Preferred ACE inhibitors for use in the present invention are ramipril, ramiprilat, lisinopril, enalapril and enalaprilat. More preferred ACE inhibitors for uses in the present invention are ramipril and ramiprilat.
  • Preferred angiotensin II receptor antagonists, pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof for use in combination with a compound of formula I include, but are not limited to, compounds: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, telmisartan and eprosartan.
  • Particularly preferred angiotensin II receptor antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil.
  • the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administered in association with an anti-obesity compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example a pancreatic lipase inhibitor e.g.
  • oriistat EP 129,748 or an appetite (satiety) controlling substance for example sibutramine (GB 2,184,122 and US 4,929,629), a cannabinoid 1 (CB1) antagonist or inverse agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example rimonabant (EP 656354 ) and as described in WO01/70700 or a melanin concentrating hormone (MCH) antagonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example as described in WO 04/004726.
  • sibutramine GB 2,184,122 and US 4,929,629
  • CBD1 cannabinoid 1
  • MCH melanin concentrating hormone
  • the compounds of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administrated in association with an anti-inflammatory agent such as glucocorticoids, non-steroidal anti- inflammatory agents (NS AID) or intestinal anti-inflammatory agents, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • an anti-inflammatory agent such as glucocorticoids, non-steroidal anti- inflammatory agents (NS AID) or intestinal anti-inflammatory agents, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.
  • glucocorticoids will include, but will not be limited to betametason, dexametason, methyl prednisolon, prednisolon, prednison, triamcinolon, hydrocortison, cortison and budesonid.
  • Suitable non-steroidal anti-inflammatory agents will include, but will not be limited to indometacin, diclofenac, ibuprofen as well as acetylsalicylic acid.
  • Suitable intestinal anti- inflammatory agents will include, but will not be limited to amino salicylates such as sulfasalazin, mesalazin, olsalazin and balsalazid.
  • the compounds of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt may be administrated in association with a cholinesterase inhibitor or an N-methyl-D-aspartate (NMD A) receptor antagonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, such as donepezil, rivastigmin or galantamin or memantin.
  • NMD A N-methyl-D-aspartate
  • a method of treating and/or preventing metabolic disorders in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of type 2 diabetes and its associated complications in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method of treating and/or preventing hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of dyslipidemia in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of the insulin resistance syndrome in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of cardiovascular disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of atherosclerosis in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of hypercholesterolemia in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for treating and/or preventing conditions associated with a need for improving reverse cholesterol transport in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for treating and/or preventing conditions associated with a need for decreasing intestinal cholesterol absorption in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for treating and/or preventing conditions associated with a need for increasing HDL-cholesterol levels in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for treating and/or preventing conditions associated with a need for decreasing LDL-cholesterol levels in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of inflammatory conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of Alzheimer's disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for the treatment and/or prohylaxis of arteriosclerosis in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a method for treating and/or preventing conditions associated with a need for improving HDL function in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.
  • kits comprising a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
  • kits comprising: a) a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in a first unit dosage form; b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • kits comprising: a) a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form; b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the the treatment and/or prophylaxis of metabolic disorders and its associated complications in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the the treatment and/or prophylaxis of metabolic syndrome or type 2 diabetes and its associated complications in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of dyslipidemia in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of hyperlipidaemic conditions in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of cardiovascular disease in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of atherosclerosis in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of hypercholesterolemia in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for improving reverse cholesterol transport in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for decreasing intestinal cholesterol absorption in a warm-blooded animal, such as man.
  • a compound of the formula I of such or a pharmaceutically acceptable salt or solvate thereof, or a solvate a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for increasing HDL-cholesterol levels in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for decreasing LDL-cholesterol levels in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and or prophylaxis of inflammatory conditions in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of Alzheimer's disease in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of arteriosclerosis in a warm-blooded animal, such as man.
  • a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for improving HDL function in a warm-blooded animal, such as man.
  • a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.
  • Flash column chromatography employed normal phase silica gel 60 (0.040-0.063 mm, Merck) or 1ST Isolute®SPE columns normal phase silica gel. Purifications were performed on either a Gilson preparative HPLC system with a UN triggered fraction collector, equipped with a ACE C8 5 ⁇ m 250 mm x 20 mm column, or on a Waters preparative HPLC system equipped with a Kromasil C8 10 ⁇ m 250 mm x 21.2 mm column, or on a Waters preparative HPLC system, equipped with an ACE C8 5 ⁇ m 250 mm x 50 mm column or an ACE C8 5 ⁇ m 250 mm x 20 mm column, or on a Waters FractionLynx HPLC system with a mass triggered fraction collector, equipped with a ACE C8 5 ⁇ m 100 mm x 21.2 mm column.
  • Example 8 3-[(2-Acetyl-5-benzofuranyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione l-(5-Aminobenzo[b]furan-2-yl)ethan-l-one (0.94 mmol, 164 mg) dissolved in dry CH 3 CN (2 mL) was added to crude 3-chloro-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione (0.47 mmol, 140 mg) and the reaction mixture was subjected to microwave heating single node 130°C for 10 min.
  • Example 16 3-[(4-Methoxyphenyl)amino]-l-(3-methoxypropyl)-4-phenyl-lH-pyrrole-2,5-dione 3-Chloro-l-(3-methoxypropyl)-4-phenyl-lH-pyrrole-2,5-dione (0.20 mmol, 56 mg) and 4- methoxyaniline (0.48 mmol, 59 mg) were dissolved in DMF (1 mL). The mixture was heated in a microwave reactor at 150°C for five min..
  • the reaction mixture was purified using ⁇ PLC (95% 0.1M ammonium acetate buffer:5% C ⁇ 3 CN — > 5% 0.1M ammonium acetate buffer: 95% CH 3 CN, 10 min., 25 mL/min.) to give 102 mg (29%) of the title compound.
  • Example 26 l-[(6-AminopyridiE-3-yl)methyl]-3- ⁇ [4-(iifl ⁇ oromethosy)phenyl]ami ⁇ o ⁇ -4-p! ⁇ e ⁇ iyl- lff-pyrrole-2,5-dione
  • LBD Ligand Binding Domain
  • SRC-1 human Steroid Receptor Co- Activator- 1
  • Eu 3+ An anti-6His-antibody coupled with Europium (Eu 3+ ) was used to recognize the His-tag on the LXR-LBD and Allophycocyanin (APC) coupled to streptavidin was used to recognize the biotinylated SRC-1.
  • LXRalpha or LXRbeta enhances the affinity of LXR towards SRC-1 and thereby brings Eu and APC in close proximity.
  • Eu 3+ is excited at 337 nm and emitts light at 620 nm. This emission, when in close proximity, excites APC to emit light at 665 nm.
  • Streptavidin APC 30 nM SRC-1 peptide and 0.9 ⁇ g/mL LXRalpha in buffer and LXRbeta mix; 0.06 ⁇ g/mL Eu-labelled anti-6x His Ab, 1.15 ⁇ g/mL Streptavidin APC, 90 nM SRC-1 peptide and 0.2 ⁇ g/mL LXRbeta in buffer.
  • Time-resolved fluorescence readings were done in a Wallac Victor reader at 665 nm followed by reading at 615 nm.
  • the LXR ligand, 22-R Hydroxycholesterol at 50 ⁇ M was used as the 100% control.
  • Expression vectors were prepared by inserting the ligand binding domain cD ⁇ A (complementary D ⁇ A) of human LXRalpha (amino acid 205-447) and LXRbeta (amino acid 216-461) in frame with, 3' to the yeast GAL4 transcription factor D ⁇ A binding domain and the nuclear localization signal from the T-antigen of Polyoma Virus in the eucaryotic expression vector pSG5 (Stratagene) .
  • the resulting expression vectors pSGGAL-LXRalpha and pSGGAL-LXRbeta were used in cotransfection experiments together with the pGL3 luciferase reporter plasmid containing a minimal SN40 promoter and five copies of the UAS GAL4 recognition site.
  • 2.5 ⁇ g pSGGAL-LXRalpha or beta were mixed with 25 ⁇ g pGL3 5xUAS and 22.5 ⁇ g pBluscript in 0.95 mL ice cold PBS containing approx. 4-9 milj.
  • U2/OS osteosarcoma cells were used in cotransfection experiments together with the pGL3 luciferase reporter plasmid containing a minimal SN40 promoter and five copies of the UAS GAL4 recognition site.
  • 2.5 ⁇ g pSGGAL-LXRalpha or beta were mixed with 25 ⁇ g pGL3 5xUAS and 22.5 ⁇ g pBluscript in 0.95 mL
  • the cell/D ⁇ A mixture was electroporated in 0.4 cm cuvettes at 960 ⁇ F, 230 N using a BioRad electroporator and diluted to 0.32 milj cells /mL in complete DMEM (Dulbecco's Modified Eagle Medium) medium (Gibco 31966-021). Cells from at least two electroporations were pooled in order to avoid variations between different electroportations. 25 ⁇ l diluted, electroporated cells, were seeded onto 384-well plates (0.8 x 10 4 cells/well) and the cells were allowed to adhere for 2 h at 37°C, 5% CO 2 in a cell culture incubator.
  • DMEM Dynamic Eagle Medium
  • Dilution plates with compounds in DMSO were further diluted in DMEM w/o phenol red (Gibco 11880-028) including 10% FBS (Foetal Bovine Serum), 1% PEST (Penicillin Streptomycin), 20mM Hepes, 2mM L-Glutamine and 0.36% Glucose (2.5 ⁇ l to 97.5 ⁇ l) in order to reduce DMSO concentration. 7 ⁇ l of this was added to the electroporated cells in 384-well plates and incubation was continued for 48 h in a cell culture incubator, after which cells were lysed by adding 32 ⁇ l/well LucLite luciferase substrate.
  • Luciferase activity was measured using the "Luminescence 384 protocol" in the Wallac Victor reader after 15 min. incubation at room temperature.
  • the LXR ligand, Tularik T0901317, at l ⁇ M was used as the 100% control.
  • the compounds of formula I have an EC 50 of less than 50 ⁇ mol/1 for LXRalpha and/or beta in coactivator recruitment assays and/or reporter gene assays.
  • the compounds of Examples 13 and 22 were EC 50 's of 0.15 ⁇ mol 1 and 0.11 ⁇ mol/1 in coactivator recruitment assays, respectively.
  • the compounds of the present invention exhibit improved physical and/or chemical and/or DMPK (Drug Metabolism and Pharmacokinetic) properties, for example they exhibit improved metabolic stability in vitro, and/or exhibit favourable pharmacological effects in vivo.
  • DMPK Drug Metabolism and Pharmacokinetic

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention relates to certain novel compounds of the Formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Description

Pyrrole-2 , 5-dione derivatives as Liver X receptor modulators
Field of the invention
The present invention relates to certain novel 1 -(substituted alkyl)- 3 amino- 4 phenyl- 1H- pyrrole-2,5-dione derivatives, to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1Η3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Background of the invention
Abnormalities of cholesterol and fatty acid homeostasis, that are reflected as diverse dyslipidemias, are causal of atherosclerosis and consequently cardiovascular disease (CND). This disease is one of the major health problems in industrialized countries and is reaching the same prevalence in adults in developing nations. Most studies show that statins reduce low density lipoproteins (LDL) cholesterol by 25-30% and the relative risk of coronary events by approximately 30%. While this beneficial effect is significant, effectively 70% of the treated cohort remains with unchanged risk. This has prompted intense research in order to identify other common abnormalities of lipid metabolism that if efficiently treated could improve the results of current CND therapy.
The nuclear hormone receptors LXR and β use oxysterols as natural ligands. They appear to act as cholesterol sensors with target genes that are required for cholesterol efflux from macrophages, like ATP binding casette transporter Al (ABCA1) and apoE, as well as gene products, like cholesterol ester transferase protein (CETP) and phospholipid transport protein (PLTP), that are required for the function of high density lipoprotein (HDL) in the reverse cholesterol transport. In addition, LXR upregulates lipoprotein lipase in liver and macrophages, a function that may stimulate fatty acid uptake and very low density lipoprotein (NLDL) remodeling. In the liver, LXR ligands seem to stimulate the hepatobiliary secretion of cholesterol, a pathway controlled by the ABCG5 and ABCG8. The same cholesterol transporters appear to reduce cholesterol absorption in enterocytes, therefore influencing total body cholesterol balance. These effects of LXR stimulation could explain its remarkable anti-atherosclerotic properties observed in animal models.
Recently the synthetic LXR ligands GW3965 (Glaxo) and T-0901317 (Tularik) were reported to increase glucose tolerance in fat fed obese mouse, which was interpreted to result from reduced hepatic gluconeogenesis and increased glucose uptake in adipocytes Lafitte BA et al. (Proc Νatl Acad Sci U S A. 2003 Apr 29; 100(9): 5419-24). Activation of LXR's improves glucose tolerance through coordinated regulation of glucose metabolism in liver and adipose tissue.
WOOO/21927 discloses pyrrole-2,5-diones, which are GSK-3 inhibitors and claimed to be useful in the treatment of dementias such as Alzheimer's disease, manic depression and diabetes. There is no suggestion that these compounds have activity as LXR modulators.
The term "LXR modulator" as used herein, means a small molecule that modulates the biological activities of LXRα and/or LXRβ. More specifically, such an LXR modulator either enhances or inhibits the biological activities of LXR. If such a modulator partially or completely enhances the biological activities of LXR, it is a partial or full LXR agonist, respectively. It is the object of the present invention to provide LXR modulators. Another object of this invention is to provide LXR modulator compounds being LXR agonists.
Description of the invention
According to a first aspect of the present invention there is provided a compound of formula I:
Figure imgf000004_0001
Formula I
wherein:
R1 is selected from phenyl(l-4C)alkyl wherein the phenyl is substituted by (1- 4C)alkoxycarbonyl or a group of formula NRaRb in which Ra and Rb independently represent H or (l-4C)alkyl; heteroaryl(l-4C)alkyl wherein the heteroaryl optionally is substituted by (1-4C) alkyl or a group of formula NRaRb in which Ra and Rb independently represent H or (l-4C)alkyl; or a (l-4C)alkyl group which is substituted by one or more of the following: fluoro, (l-4C)alkoxycarbonyl, (l-3C)alkylthio or (l-3C)alkoxy optionally substituted by one or more fluoro; R2 is phenyl; R3 is selected from phenyl, indolyl or benzofuranyl each optionally substituted by one or more of the following: (l-3C)alkanoyl, (l-3C)alkoxy optionally substituted by one or more fluoro; (l-3C)alkylthio; or a group of formula NRaRb in which Ra and Rb independently represent H, (l-3C)alkyl or (l-3C)alkanoyl or Ra and Rb together with the nitrogen atom to which they are attached represent morpholino, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.
The term heteroaryl means pyridyl, furyl or isoxazolyl each of which is optionally substituted by one or more of the following: (l-4C)alkyl or a group of formula NRaRb in which Ra and Rb independently represent H or (l-4C)alkyl.
Further values of R1, R2 and R3in compounds of formula I now follow. It will be understood that such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
R1 is selected from 2-mefhoxyethyl, 2-methylthioethyl, 2,2,2-trifluoroethyl, 3- methoxypropyl, 3,3,3-trifluoropropyl, ethoxycarbonylmethyl, 4-NN-dimethylaminobenzyl, 4- methoxycarbonylbenzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 6-amino- 3-pyridylmethyl, 3-furylmethyl or (5-methylisoxazol-3yl)methyl.
R3 is selected from phenyl, 4-methoxyphenyl, 4-methylthiophenyl, 4-morpholinophenyl, 4-acetylaminophenyl, 4-trifluoromethoxyphenyl, 4-difluoromethoxyphenyl or 2-acetyl-5- benzofuranyl.
In a first group of compounds of formula I
R1 is selected from 2-methoxyethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 3- methoxypropyl, ethoxycarbonylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4- pyridylmethyl, 6-amino-3-pyridylmethyl or (5-methylisoxazol-3yl)methyl; R2 is phenyl;
R is selected from phenyl, 4-methoxyphenyl, 4-acetylaminophenyl, 4- difluoromethoxyphenyl or 4-morpholinophenyl.
In a second group of compounds of formula I
R1 is selected from 2-methoxyethyl, 6-amino-3-pyridylmethyl, 3-pyridylmethyl or 2,2,2- trifluoroethyl; R2 is phenyl; and R is selected from 4-methoxyphenyl, 4-difluoromethoxyphenyl, 4- trifluoromethoxyphenyl or 4-morpholinophenyl.
In a third group of compounds of formula I
R1 is selected from 2,2,2-trifluoroethyl, 3-furylmethyl, 6-amino-3-pyridylmethyl or 3- pyridylmethyl; R2 is phenyl; and
R3 is selected from 4-methoxyphenyl , 4-difluoromethoxyphenyl, 4-morpholinophenyl or 2-acetyl-5 -benzofuranyl .
In a fourth group of compounds of formula I
E1 is selected from 6-amino-3~pyridylmβthyl or 2-methoxyethyl; R2 is phenyl; and R3 is selected from 4-morpholinophenyl, 4-trifluoromethoxyphenyl or 4- difluoromethoxyphenyl.
In a fifth group of compounds of formula I R1 is selected from 6-amino-3-pyridylmethyl, 3-furylmethyl, 3-pyridylmethyl, 2,2,2- trifluoroethyl or 2-methoxyethyl; R is phenyl; and
R3 is selected from 4-morpholinophenyl, 4-methoxyphenyl, 4-trifluoromethoxyphenyl, 4- difluoromethoxyphenyl or 2-acetyl-5-benzofuranyl.
The compounds of formula I have activity as medicaments. In particular the compounds of formula I are LXR agonists.
Specific compounds of the invention are one or more of the following: 1 -(2-Methoxyethyl)-3-[(4-methoxyphenyl)amino]-4-phenyl- lH-pyrrole-2,5-dione
3- { [4-(Difluoromethoxy)phenyl] amino } - 1 -(2-methoxyethyl)~4-phenyl- 1 H-pyrrole-2,5- dione
N-(4- { [2,5-Dihydro- 1 -(2-methoxyethyl)-2,5-dioxo-4-phenyl- 1 H-pyrrol-3- yl]amino }phenyl)-acetamide 1 -(2-Methoxyethyl)-3- { [4(methylthio)phenyl] amino } -4-phenyl- 1 H-pyrrole-2,5-dione
3-[(2-Acetyl-5-benzofuranyl)amino]-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione l-(2-Methoxyethyl)-3-[(4-mo holin-4-ylphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione
3-[(4-Morpholin-4-ylphenyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-235- dione 3-[(2-Acetyl-5-benzofuranyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione
3-Phenyl- 1 -(pyridin-3 -ylmethyl)-4- { [4-(trifluoromethoxy)phenyl] amino } - 1 H-pyrrole-2,5- dione
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5-dione 3-Anilino-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5-dione
3-{[4-(Difluoromethoxy)phenyl]amino}-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione l-[4-(Dimethylamino)benzyl]-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5- dione
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-4-ylmethyl)-lH-pyrrole-2,5-dione
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-2-ylmethyl)-lH-pyrrole-2,5-dione 3-[(4-Methoxyphenyl)amino]-l-(3-methoxypropyl)-4-phenyl-lH-pyrrole-2,5-dione
Methyl 4-({3-[(4-methoxyphenyl)amino]-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyrrol-l- yl } methyl)benzoate
3-[(4-Methoxyphenyl)amino]-l-[2-(methylthio)ethyl]-4-phenyl-lH-pyrrole-2,5-dione
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(3,3,3-trifluoropropyl)-lH-pyrrole-2,5-dione l-(3-Furylmethyl)-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(2,2,2-trifluoroethyl)-lH-pyrrole-2,5-dione
3-[(4-Methoxyphenyl)amino]-l-[(5-methylisoxazol-3-yl)methyl]-4-phenyl-lH-pyrrole-2,5- dione
Ethyl {3-[(4-methoxyphenyl)amino]-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyrrol-l- yl} acetate
3-Phenyl- 1 -(2,2,2-trifluoroethyl)-4- { [4-(trifluoromethoxy)phenyl]amino } - lΗ-pyrrole-2,5- dione l-[(6-Aminopyridin-3-yl)methyl]-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5- dione 1 -[(6-Aminopyridin-3-yl)methyl]-3- { [4-(difluoromethoxy)phenyl]amino }-4-phenyl- 1H- pyrrole-2,5-dione and l-[(6-Aminopyridine-3-yl)methyl]-3-[(4-morpholin-4-ylphenyl)amino]-4-phenyl-l-Η- pyrrole-295-dione, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.
Certain compounds of the present invention may exist as tautomers. It is to be understood that the present invention encompasses all such tautomers.
Methods of preparation
The compounds of the invention may be prepared as outlined below. However, the invention is not limited to these methods. The compounds may also be prepared as described for structurally related compounds in the prior art. The reactions can be carried out according to standard procedures or as described in the experimental section.
Compounds of formula I may be prepared by reacting a compound of formula II
Figure imgf000008_0001
in which R »2 a „„nd J R τ>3 are as previously defined with a compound of formula HI
R^H
Figure imgf000008_0002
in which R1 is as previously defined in the presence of a dialkyl azodicarboxylate, for example diethyl azodicarboxylate, and a phosphine, for example triphenylphosphine, optionally in the presence of an inert organic liquid for example an ether e.g. tetrahydrofuran at a temperature in the range of 0°C to 200°C.
Compounds of formula I may also be prepared by reacting a compound of formula IV
Figure imgf000008_0003
IV
in which R1 and R2 are as previously defined and Y is a leaving group for example halo e.g. CI, Br or I with a compound of formula V R3NH2 V in which R is as previously defined optionally in the presence of an inert organic liquid for example dimethylformamide optionally in the presence of a base for example potassium carbonate at a temperature in the range of 0°C to 250°C.
Compounds of formula II may be prepared by reacting a compound of formula NI
Figure imgf000009_0001
VI
in which R2 is as previously defined and Y is a leaving group for example halo eg CI, Br or I with a compound of formula N R3ΝH2 V in which R is as previously defined optionally in the presence of an inert organic liquid for example dimethylformamide and optionally in the presence of a base for example triethylamine at a temperature in the range of 0°C to 250°C.
Compounds of formula III and V are commercially available or may be prepared by methods known to those skilled in the art.
Compounds of formula IN may be prepared by reacting a compound of formula NLT
Figure imgf000010_0001
VII
in which R is as previously defined and Y is a leaving group for example halo eg CI, Br or I with a compound of formula NLU R1ΝH2 Nm in which R1 is as previously defined optionally in the presence of an organic liquid, for example glacial acetic acid at a temperature in the range of 0°C to 200°C.
Compounds of formula IN may also be prepared by reacting a compound of formula NI with a compound of formula XI R*L XI in which R is as as previously defined and L is a leaving group for example halo eg CI, Br or I in the presence of an inert organic liquid for example dimethylformamide and optionally in the presence of a base for example potassium carbonate at a temperature in the range of -78°C to 200°C.
Compounds of formula NI may be prepared by reacting a compound of formula LX
Figure imgf000010_0002
IX in which R is as previously defined with a halogenating agent for example oxalyl chloride optionally in the presence of an inert organic liquid for example dichloromethane and optionally in the presence of a catalytic amount of dimethylformamide at a temperature in the range of 0°C to 200°C.
Compounds of formula Nil may be prepared by reacting a compound of formula X
Figure imgf000011_0001
X
in which R is as previously defined with a halogenating agent for example thionyl chloride optionally in the presence of an inert organic liquid for example dichloromethane and optionally in the presence of a base for example pyridine at a temperature in the range of O°C to 200°C.
Compounds of formula VIII, LX, X and XI are commercially available or may be prepared by methods known to those skilled in the art.
Certain compounds of formula II and IN are believed to be novel and are claimed herein as useful intermediates in the preparation of compounds of formula I.
The compounds of the invention may be isolated from their reaction mixtures using conventional techniques.
Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative and in some occasions, more convenient manner, the individual process steps mentioned hereinbefore may be performed in different order, and/or the individual reactions may be performed at different stage in the overall route (i.e. chemical transformations may be performed upon different intermediates to those associated hereinbefore with a particular reaction).
The expression "inert organic liquid" refers to a solvent which does not react with the starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
Pharmaceutical preparations
The compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.
Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.0001-100 mg/kg body weight, preferably 0.01-10 mg kg body weight.
Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.7 mg to 700 mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg and 250 mg.
According to a further aspect of the invention there is thus provided a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers. Pharmacological properties
The compounds of formula I are useful for normalization of cholesterol homeostasis, decreasing intestinal cholesterol absorption, improving reverse cholesterol transport, improving HDL functionality, increasing HDL-cholesterol levels, decreasing LDL- cholesterol levels, decreasing cholesterol content of apoB -containing lipoproteins, stimulating cholesterol efflux from vascular cells and/or decreasing the inflammatory response of vascular cells. As a consequence of these properties the compounds of formula I are expected to have anti-atherosclerotic effects.
The compounds of formula I are useful in the prevention or treatment of cardiovascular disease in a mammal, particularly a human. The compounds of formula I are useful in the prevention or treatment of atherosclerosis in a mammal, particularly a human. Cardiovascular disease includes but is not limited to conditions associated with atherosclerosis, arteriosclerosis, hypercholesterolemia, and other kinds of dyslipidemia that increase the risk for cardiovascular disease. In particular the compounds of formula I are useful in the treatment or prevention of cardiovascular disease, especially those involving atherosclerosis and hypercholesterolemia.
The compounds of formula I also serve to prevent lipid accumulation in, or remove lipids from, tissue deposits such as atherosclerotic plaques or xanthomas in a patient with atherosclerotic disease manifest by clinical signs such as angina, claudication, bruits, one that has suffered a mycardial infarction or transient ischemic attack, or one diagnosed by angiography, sonography or MRI.
The compounds of formula I also serve to prevent or reduce the risk of developing atherosclerosis, as well as for halting or slowing the progression of atherosclerotic disease once it has become clinically evident, comprising the administration of a prophylactically or therapeutically effective amount, as appropriate, of a compound of formula I to a mammal, including a human, who is at risk of developing atherosclerosis or who already has atherosclerotic disease. Atherosclerosis encompasses vascular diseases and conditions that are recognized and understood by physicians practicing in the relevant fields of medicine. Atherosclerotic cardiovascular disease including restenosis following revascularization procedures, coronary heart disease (also known as coronary artery disease or ischemic heart disease), cerebrovascular disease including multi-infarct dementia, and peripheral vessel disease including erectile dysfunction are all clinical manifestations of atherosclerosis and are therefore encompassed by the terms "atherosclerosis" and "atherosclerotic disease".
The present compounds of formula I are also useful for the prophylaxis and/or treatment of clinical conditions associated with atherosclerosis such as inherent or induced hypercholesterolemia as well as inherent or induced reduced sensitivity to insulin (insulin resistance syndrome also known as metabolic syndrome) and associated metabolic disorders. These clinical conditions will include, but will not be limited to, general obesity, abdominal obesity, arterial hypertension, hyperinsulinaemia, hyperglycaemia, type 2 diabetes and the dyslipidaemia characteristically appearing with insulin resistance. This dyslipidaemia, also known as the atherogenic lipoprotein profile, is characterised by moderately elevated non-esterified fatty acids, elevated NLDL triglyceride rich particles, high ApoB levels, low HDL levels associated with low apoAI levels in the presence of small, dense, LDL particles, phenotype B.
The compounds of formula I are expected to be useful in treating patients with combined or mixed hyperlipidemias and dyslipidemias, especially low HDL levels with or without other manifestations of the metabolic syndrome.
Treatment with the compounds of formula I are expected to lower the cardiovascular morbidity and mortality associated with atherosclerosis due to their antidyslipidaemic as well as antiinflammatory properties. The cardiovascular disease conditions include macro- angiopathies of various internal organs causing myocardial infarction, congestive heart failure, cerebrovascular disease and peripheral arterial insufficiency of the lower extremities. The insulin sensitizing effect of the compounds of formula I is also expected to prevent or delay the development of type 2 diabetes from the metabolic syndrome and diabetes of pregnancy. Therefore the development of long-term complications associated with chronic hyperglycaemia in diabetes mellitus such as the micro-angiopathies causing renal disease, retinal damage and peripheral vascular disease of the lower limbs are expected to be delayed. The compounds of formula I may also be useful for the prevention or treatment of inflammation and neurodegenerative diseases or neurological disorders. Accordingly, this invention also provides a method for preventing or treating inflammation in the CNS and a method for preventing or treating neurodegenerative diseases or disorders characterized by neuron degeneration, neuron injury or impaired plasticity or inflammation in the CNS. The neurodegenerative diseases or conditions characterized by neuron degeneration and inflammation will include but will not be limited to stroke, Alzheimer's disease, fronto- temporal dementias (taupathies), peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis. The compounds of formula I are useful in preventing or treating inflammatory conditions or diseases. These diseases or conditions will include but will not be limited to atherosclerotic diseases such as angina pectoris and myocardial infarction as well as inflammatory bowel diseases or conditions such as Crohn's disease, ulcerative colitis and distal proctitis. Compounds of formula I may also be used in other inflammatory conditions of the lung including asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease and pneumonia bronchitis.
Furthermore the compounds of formula I may be useful in treatment of various conditions outside the cardiovascular system whether or not associated with insulin resistance, like polycystic ovarian syndrome, obesity and cancer. The present invention provides a method of treating and/or preventing dyslipidemias, the insulin resistance syndrome and/or metabolic disorders (as defined above) comprising the administration of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing type 2 diabetes comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof. The present invention provides a method of treating and/or preventing cardiovascular disease comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing atherosclerosis comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing hypercholesterolemia comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing conditions associated with a need for improving reverse cholesterol transport comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing conditions associated with a need for decreasing intestinal cholesterol absorption comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing conditions associated with a need for increasing HDL-cholesterol levels comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing conditions associated with a need for decreasing LDL-cholesterol levels comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof. The present invention provides a method of treating and/or preventing inflammatory conditions comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing Alzheimer's disease comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing arteriosclerosis comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing conditions associated with a need for improving HDL function comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
The present invention provides a method of treating and/or preventing hyperlipidemic conditions comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.
In a further aspect the present invention provides the use of a compound of formula I as a medicament.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prohylaxis of dyslipidemic conditions.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prohylaxis of insulin resistance and/or metabolic disorders. In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of cardiovascular disease.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of atherosclerosis.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of hypercholesterolemia.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for improving reverse cholesterol transport.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for decreasing intestinal cholesterol absorption.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for increasing HDL-cholesterol levels.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for decreasing LDL-cholesterol levels.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of inflammatory conditions. In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of Alzheimer's disease.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of arteriosclerosis.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of type 2 diabetes.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for improving HDL function.
In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidemic conditions.
Combination Therapy
The compounds of the invention may be combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes, inflammation and obesity. The compounds of the invention may be combined with another therapeutic agent that decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol. In patients with diabetes mellitus the compounds of the invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.
In another aspect of the present invention, the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with cholesterol biosynthesis inhibitors, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable cholesterol biosynthesis inhibitors include HMG CoA reductase inhibitors, squalene synthesis inhibitors and squalene epoxidase inhibitors. A suitable squalene synthesis inhibitor is squalestatin 1 and a suitable squalene epoxidase inhibitor is NB-598. In this aspect of the invention, the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administrated in association with an HMG CoA reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitably the HMG CoA reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are statins well known in the art. Particular statins are selected from the group consisting of atorvastatin, fluvastatin, pitavastatin, lovastatin, mevastatin, nicostatin, nivastatin, pravastatin and simvastatin, or a pharmaceutically acceptable salt, especially sodium or calcium, solvate, solvate of such a salt or a prodrug thereof. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A particularly preferred statin is, however, rosuvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A preferable particular statin is rosuvastatin calcium salt.
In the present application, the term "cholesterol biosynthesis inhibitors" also includes chemical modifications of the HMG CoA reductase inhibitors, squalene synthesis inhibitors and squalene epoxidase inhibitors, such as esters, prodrugs and metabolites, whether active or inactive.
In another aspect of the present invention, the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,, may be administered in association with an inhibitor of the ileal bile acid transport system (IB AT inhibitor), or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable compounds possessing IBAT inhibitory activity have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/07449, WO 98/03818, WO 98/38182, WO 99/32478, WO 99/35135, WO 98/40375, WO 99/35153, WO
99/64409, WO 99/64 10, WO 00/01687, WO 00/47568, WO 00/61568, WO 00/62810, WO 01/68906, DE 19825804, WO 00/38725, WO 00/38726, WO 00/38727, WO 00/38728, WO 00/38729, WO 01/68906, WO 01/66533, WO 02/32428, WO 02/50051, EP 864 582, EP 489 423, EP 549 967, EP 573 848, EP 624 593, EP 624 594, EP 624 595 and EP 624 596 and the contents of these patent applications are incorporated herein by reference. Further suitable compunds possessing IBAT inhibitory activity have been described in WO 94/24087, WO 98/56757, WO 00/20392, WO 00/20393, WO 00/20410, WO 00/20437, WO 01/34570, WO 00/35889, WO 01/68637, WO 02/08211, WO 03/020710, WO 03/022825, WO 03/022830, WO 03/022286, WO 03/091232, WO 03/106482, JP 10072371, US 5070103, EP 251 315, EP 417 725, EP 869 121, EP 1 070 703 and EP 597 107 and the contents of these patent applications are incorporated herein by reference. Particular classes of IBAT inhibitors suitable for use in the present invention are benzothiazepines, and the compounds described in the claims, particularly claim 1, of WO 00/01687, WO 96/08484 and WO 97/33882 are incorporated herein by reference. Other suitable classes of LB AT inhibitors are the 1,2-benzothiazepines, 1,4-benzothiazepines and 1,5-benzothiazepines. A further suitable class of IBAT inhibitors is the 1,2,5- benzothiadiazepines .
One particular suitable compound possessing IBAT inhibitory activity is (3R,5R)-3-butyl- 3-ethyl- 1 , 1 -dioxido-5-phenyl-2,3 ,4,5-tetrahydro- 1 ,4-benzothiazepin-8-yl β-D- glucopyranosiduronic acid (EP 864 582). A further suitable compound possessing IBAT inhibitory activity is S-8921 (EP 597 107).
In another aspect of the present invention, the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a cholesterol absorption antagonist , or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example azetidinones such as ezetrol (zetia, ezetimibe) and those described in US 5,767,115 which are incorporated herein by reference. Suitable compounds possessing cholesterol absorption antagonist activity have been described, see for instance the compounds described in WO 02/50027, WO 02/66464, WO 04/005247, WO 04/000803, WO 04/000804 and WO 04/000805 which are incorporated herein by reference. In another aspect of the present invention, the compund of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a bile acid sequestrant or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable bile acid sequestrants include cholestyramine, cholestipol and cosevelam hydrochloride.
In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a peroxisome proliferator-activated receptor (PPAR) modulating agent. PPAR modulating agents include but are not limited to a PPAR alpha and/or gamma and/or delta agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma and/or delta agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO 98/57941, WO 01/40170, WO 04/000790, WO 04/000295, WO 04/000294, WO 03/051822, WO 03/051821, WO 02/096863, WO 03/051826, WO 02/085844, WO 01/40172, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all incorporated herein by reference. Particularly a PPAR alpha and/or gamma and/or delta agonist refers to muraglitazar (BMS 298585), rivoglitazone (CS-011), netoglitazone (MCC-555), balaglitazone (DRF-2593, NN-2344), clofibrate, fenofibrate, bezafibrate, gemfibrozil , ciprofibrate, pioglitazone, rosiglitazone, ANE-0847, ANE-8134, CLX-0921, DRF-10945, DRF-4832, LY-518674, LY-818, LY-929, 641597, GW-590735, GW-677954, GW-501516, MBX-102, OΝO-5129, KRP-101, R-483 (BM131258), TAK- 559 or TAK-654. Particularly a PPAR alpha and/or gamma and/or delta agonist refers to tesaglitazar ((S)-2-ethoxy-3-[4-(2- {4-methanesulphonyl- oxyphenyl}ethoxy)ρhenyl]propanoic acid) and pharmaceutically acceptable salts thereof. In yet another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a pyruvate dehydrogenase kinase (PDK) inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, or modulators of nuclear receptors such as retenoid X receptor (RXR), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a cholesteryl ester transfer protein (CETP) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example those referenced and described in WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference.
In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a microsomal transfer protein (MTP) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example implipatide and those described in WO 03/004020, WO 03/002533, WO 02/083658 and WO 00/242291, and the contents of these patent applications are incorporated herein by reference, or those described in Science, 282, 751-54, 1998 which are incorporated herein by reference. In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a nicotinic acid derivative, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, including slow release and combination products, for example, nicotinic acid (niacin), acipimox, nicofuranose, NIASPAN® and niceritrol.
In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a acyl coenzymA: cholesterol O-acyltransferase (ACAT) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example CS-505, eflucimibe (F-12511) and SMP-797.
In yet another aspect of the invention, the compound of formula I, association with modulators of nuclear receptors such as farnesoid or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in X receptor (FXR), or pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a phytosterol compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example stands.
In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with other therapies for the treatment of metabolic syndrome or type 2 diabetes and its associated complications, these include biguanide drugs, for example metformin, phenformin and buformin, insulin (synthetic insulin analogues, amylin) and oral antihyperglycemics (these are divided into prandial glucose regulators and alpha- glucosidase inhibitors). An example of an alpha-glucosidase inhibitor is acarbose or voglibose or miglitol. An example of a prandial glucose regulator is repaglinide or nateglinide.
In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, gliquidone, chloropropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolcylamide and tolazamide. Preferably the sulfonylurea is glimepiride or glibenclamide (glyburide). More preferably the sulfonylurea is glimepiride. Therefore the present invention includes administration of a compound of the present invention in conjunction with one, two or more existing therapies described in this paragraph. The doses of the other existing therapies for the treatment of type 2 diabetes and its associated complications will be those known in the art and approved for use by regulatory bodies for example the FDA and may be found in the Orange Book published by the FDA. Alternatively smaller doses may be used as a result of the benefits derived from the combination.
In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with an antihypertensive compound for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha andrenergic blocker, a beta andrenergic blocker, a mixed alpha/beta andrenergic blocker, an andrenergic stimulant, calcium channel blocker, an AT-1 blocker, a saluretic, a diuretic or a vasodilator, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Particular ACE inhibitors or pharmaceutically acceptable salts, solvates, solvate of such salts or prodrugs thereof, including active metabolites, which can be used in combination with a compound of formula I include but are not limited to, the following compounds: alacepril, alatriopril, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril- glutathione, ceranopril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, hemorphin-4, imidapril, indolapril, indolaprilat, lisinopril, lyciumin A, lyciumin B, moexipril, moexiprilat, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, zofenopril and zofenoprilat. Preferred ACE inhibitors for use in the present invention are ramipril, ramiprilat, lisinopril, enalapril and enalaprilat. More preferred ACE inhibitors for uses in the present invention are ramipril and ramiprilat. Preferred angiotensin II receptor antagonists, pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof for use in combination with a compound of formula I include, but are not limited to, compounds: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, telmisartan and eprosartan. Particularly preferred angiotensin II receptor antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil.
In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with an anti-obesity compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example a pancreatic lipase inhibitor e.g. oriistat (EP 129,748) or an appetite (satiety) controlling substance for example sibutramine (GB 2,184,122 and US 4,929,629), a cannabinoid 1 (CB1) antagonist or inverse agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example rimonabant (EP 656354 ) and as described in WO01/70700 or a melanin concentrating hormone (MCH) antagonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example as described in WO 04/004726.
In another aspect of the invention, the compounds of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administrated in association with an anti-inflammatory agent such as glucocorticoids, non-steroidal anti- inflammatory agents (NS AID) or intestinal anti-inflammatory agents, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable glucocorticoids will include, but will not be limited to betametason, dexametason, methyl prednisolon, prednisolon, prednison, triamcinolon, hydrocortison, cortison and budesonid. Suitable non-steroidal anti-inflammatory agents will include, but will not be limited to indometacin, diclofenac, ibuprofen as well as acetylsalicylic acid. Suitable intestinal anti- inflammatory agents will include, but will not be limited to amino salicylates such as sulfasalazin, mesalazin, olsalazin and balsalazid.
In another aspect of the invention, the compounds of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administrated in association with a cholinesterase inhibitor or an N-methyl-D-aspartate (NMD A) receptor antagonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, such as donepezil, rivastigmin or galantamin or memantin.
Therefore in an additional feature of the invention, there is provided a method of treating and/or preventing metabolic disorders in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Therefore in an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of type 2 diabetes and its associated complications in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Therefore in an additional feature of the invention, there is provided a method of treating and/or preventing hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of dyslipidemia in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of the insulin resistance syndrome in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of cardiovascular disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of atherosclerosis in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of hypercholesterolemia in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for treating and/or preventing conditions associated with a need for improving reverse cholesterol transport in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. In an additional feature of the invention, there is provided a method for treating and/or preventing conditions associated with a need for decreasing intestinal cholesterol absorption in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for treating and/or preventing conditions associated with a need for increasing HDL-cholesterol levels in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for treating and/or preventing conditions associated with a need for decreasing LDL-cholesterol levels in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of inflammatory conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of Alzheimer's disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for the treatment and/or prohylaxis of arteriosclerosis in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In an additional feature of the invention, there is provided a method for treating and/or preventing conditions associated with a need for improving HDL function in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in simultaneous, sequential or separate administration with an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.
According to a further aspect of the present invention there is provided a kit comprising a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in a first unit dosage form; b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and c) container means for containing said first and second dosage forms.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form; b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and c) container means for containing said first and second dosage forms.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the the treatment and/or prophylaxis of metabolic disorders and its associated complications in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the the treatment and/or prophylaxis of metabolic syndrome or type 2 diabetes and its associated complications in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of dyslipidemia in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of hyperlipidaemic conditions in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of cardiovascular disease in a warm-blooded animal, such as man. According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of atherosclerosis in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of hypercholesterolemia in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for improving reverse cholesterol transport in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for decreasing intestinal cholesterol absorption in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, of such or a pharmaceutically acceptable salt or solvate thereof, or a solvate a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for increasing HDL-cholesterol levels in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for decreasing LDL-cholesterol levels in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and or prophylaxis of inflammatory conditions in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of Alzheimer's disease in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of arteriosclerosis in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of a conditions associated with a need for improving HDL function in a warm-blooded animal, such as man.
According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.
Examples
Abbreviations
DMF N, N' -dimethylformamide
DMSO dimethylsulfoxide
EtOAc ethyl acetate
EtOH ethanol
HPLC high performance liquid chromatography
LC-MS liquid chromatography mass spectroscopy
NMR nuclear magnetic resonance
THF tetrahydrofuran UN ultra violet rt room temperature rnin. minutes b broad bs broad singlet d doublet dd doublet of doublets m multiplet s singlet t triplet
General Experimental Procedures
Flash column chromatography employed normal phase silica gel 60 (0.040-0.063 mm, Merck) or 1ST Isolute®SPE columns normal phase silica gel. Purifications were performed on either a Gilson preparative HPLC system with a UN triggered fraction collector, equipped with a ACE C8 5 μm 250 mm x 20 mm column, or on a Waters preparative HPLC system equipped with a Kromasil C8 10 μm 250 mm x 21.2 mm column, or on a Waters preparative HPLC system, equipped with an ACE C8 5 μm 250 mm x 50 mm column or an ACE C8 5 μm 250 mm x 20 mm column, or on a Waters FractionLynx HPLC system with a mass triggered fraction collector, equipped with a ACE C8 5μm 100 mm x 21.2 mm column. 1H ΝMR spectra were obtained on a Narian Unity Plus, 400 MHz, operating at 9.3 T, equipped with a 5 mm switchable probe with an inner X-coil, for solutions in CDCI3 [residual CHC13 (δπ 7.23 ppm) as internal standard], CH3GSW3 [residual CH3CN (δπ 1.94 ppm) as internal standard], or DMSO--f6 [residual DMSO (δπ 2.50 ppm) as internal standard] at 300K. Chemical shifts are given in ppm. Microwave heating was performed using single node heating in a Smith Creator from Personal Chemistry, Uppsala, Sweden. Synthesis of Starting Materials and Intermediates
3-ChIoro-4-phenylfuran-2,5-dione
To an ice cold solution of phenylmaleic anhydride (5.74 mmol, 1.0 g) in thionyl chloride (6.0 mL) was added drop wise pyridine (11.4 mmol, 0.9 g). The reaction mixture was stirred for 60 min at 0°C, followed by heating to 75°C for 20 min.. The reaction mixture was cooled to room temperature and the thionyl chloride was removed in vacuo. The crude residue was suspended in toluene (10 mL), refluxed for 10 min., followed by filtration of the hot mixture. The filtrate was concentrated to give 1.15 g (96%) of the title. 1H NMR (400 MHz, CDC13) δ 8.05-8.00 (m, 2H), 7.59 - 7.51 (m, 3H).
3-Chloro-l-(2-methoxyethyI)-4-phenyl-lH-pyrrole-2,5-dione
A solution of 3-chloro-4-phenylfuran-2,5-dione (0.20 mmol, 42 mg) and 2- methoxyethylamine (0.20 mmol, 15 mg) in glacial acetic acid (1 mL) was heated in a microwave reactor at 120°C for two min.. After cooling, the solvent was evaporated at reduced pressure. The crude product was used without purification.
3-Chloro-4-phenyI-l-(pyridin-3-ylmethyl)-llB[-pyrrole-2,5-dione
A solution of 3-chloro-4-phenylfuran-2,5-dione (1.00 mmol, 209 mg) and 3- (aminomethyl)-pyridine (1.00 mmol, 26 mg) in glacial acetic acid (4 mL) was heated in a microwave reactor at 120°C for two min.. After cooling, the solvent was evaporated at reduced pressure. The crude product was used without purification.
3-Chloro-l-[4-(dimethyIamino)bensyl]-4-phenyl-lH-pyrrole-25,5-dione To a solution of 3-chloro-4-phenylfuran-2,5-dione (0.20 mmol, 42 mg) and 4- dimethylaminobenzylamine dihydrochloride (0.20 mmol, 45 mg) in glacial acetic acid (1 mL) was added triethylamine (0.40 mmol). The mixture was heated in a microwave reactor at 120°C for two min.. After cooling, the solvent was evaporated at reduced pressure. The reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN -» 100% CH3CN). 3-Chloro-4-phenyl-l-(pyridin-2-ylmethyl)-lH-pyrrole-2,5-dione
A solution of 3-chloro-4-phenylfuran-2,5-dione (0.20 mmol, 42 mg) and 2-ammomethyl- pyridine (0.20 mmol, 22 mg) in glacial acetic acid (1 mL) was heated in a microwave reactor at 120°C for two min.. After cooling, the solvent was evaporated at reduced pressure. The crude product was used without purification.
3-Chloro-l-(3-methoxypropyl)-4-phenyl-lH-pyrrole-2,5-dione
A solution of 3-chloro-4-phenylfuran-2,5-dione (0.20 mmol, 42 mg) and l-amino-3- methoxypropane (0.20 mmol, 18 mg) in glacial acetic acid (1 mL) was heated in a microwave reactor at 120°C for two min.. After cooling, the solvent was evaporated at reduced pressure. The crude product was used without purification.
Methyl 4-[(3-chloro-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyrrol-l-yl)methyl]benzoate
A solution of 3-chloro-4-phenylfuran-2,5-dione (0.24 mmol, 50 mg) and methyl 4- (aminomethyl)benzoate (0.24 mmol, 40 mg) in glacial acetic acid (1 mL) was heated in a microwave reactor at 120°C for two min.. After cooling, the solvent was evaporated at reduced pressure. The crude product was used without purification.
3-Chloro-l-[2-(methylthio)ethyl]-4-phenyI-lH-pyrroIe-2,5-dione A solution of 3-chloro-4-phenylfuran-2,5-dione (1.00 mmol, 209 mg) and 2-aminoethyl methyl sulphide (1.00 mmol, 91 mg) in glacial acetic acid (2 mL) was heated in a microwave reactor at 120°C for two min.. After cooling, the solvent was evaporated at reduced pressure. The residue was partitioned between water and CH2CI2. The organic phase was evaporated and the crude product was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN — > 100% CH3CN) to give 152 mg (54%) of the title compound. 1H NMR (400 MHz, CDC13): δ 7.97-7.90 (m, 2H), 7.53-7.47 (m, 3H), 3.86 (t, J=6.8 Hz, 2H), 2.78 (t, J=6.8 Hz, 2H), 2.16 (s, 3H).
3-Hydroxy-4-phenyl-lH-pyrrole-2,5-dione Prepared according to literature procedure: C. S. Rooney, et al; J. Med. Chem., Vol. 26 (1983) pp 700-714. 3-Chloro-4-phenyl-LH-pyrrole-2,5-dione
To a suspension of 3-hydroxy-4-phenyl-lH-pyrrole-2,5-dione (25.0 g, 0.13 mol) in dichloromethane (600 mL) under nitrogen was added DMF (36 mL). The suspension was cooled to ice temperature and treated with oxalyl chloride (40.0 g, 0.32 mol). The reaction mixture was subsequently refluxed overnight. After cooling to room temperature silica gel was added and the reaction mixture evaporated to dryness and subjected to flash chromatography (hexane:EtOAc 80:20). Trituration with dichloromethane, filtration and drying gave 17.6 g (64%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.96-7.89 (m, 2H), 7.88-7.77 (bs, 1H), 7.55-7.45 (m, 3H).
3-[(4-Methoxyphenyl)amino]-4-phenyl-lflr-pyrrole-2,5-dione
To a solution of 3-chloro-4-phenyl-lH-pyrrole-2,5-dione (4.84 mmol, 1.0 g) in dry DMF (5 mL) was added 4-methoxyaniline (4.87 mmol, 600 mg) and the reaction mixture was subjected to microwave heating single node 150°C, 15 min, followed by 150°C, 10 min. The solvent was evaporated, and the crude mixture was partitioned between dichloromethane and water. The organic phase was dried over anhydrous Na2SO4, concentrated and the residue was purified on SiO2 (Ηeptane:EtOAc, 3:1 — » 2:1) to give 457 mg (32%) of the title compound. 1H NMR (400 MHz, DMSO- ) δ 10.62 (s, 1H), 9.27 (s, 1H), 7.09-6.99 (m, 3H), 6.87-6.83 (m, 2H), 6.65-6.60 (m, 2H), 6.52-6.47 (m, 2H), 3.58 (s, 3H).
3-Phenyl-4-{[4-(trifluoromethoxy)phenyl]amino}-lH-pyrrole-2,5-dione
3-Chloro-4-phenyl-lH-pyrrole-2s5-dione (2.00 mmol, 415 mg), 4-difluoromethoxyaniline (2.00 mmol, 354 mg) and triethylamine (2.00 mmol, 202 mg) were dissolved in DMF (5 mL). The mixture was stirred at 70°C for 20 hours. After cooling, the reaction mixture was filtrated and purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN -» 100% CH3CN) to give 320 mg (46%) of the title compound. 1H NMR (400 MHz, CDC13): δ 7.22 (bs, 1H), 7.22-7.09 (m, 3H), 7.02-6.97 (m, 2H), 6.91-6.85 (m, 2H), 6.69-6.63 (m, 2H). tert-Butyl [5-(bromomethyl)pyridin-2-yl] carbamate
Prepared according to literature procedure: WO0066557 Linschoten, M. et al, Astrazeneca AB, Nov. 9, 2000.
tert-Butyl {5-[(3-chloro-2,5-dioxo-4-phenyl-2,5-dihydro-lJy-pyrrol-l- yl)methyl]pyridin-2-yl}carbamate
3-Chloro-4-phenyl-lH-ρyrrole-2,5-dione (1.55 g, 7.47 mmol) was dissolved in DMF (25 mL) under nitrogen atmosphere and cooled in an ice-bath. tert-Butyl [5- (bromomethyl)pyridin-2-yl]carbamate (2.14 g, 7.46 mmol) was added followed by anhydrous potassium carbonate (1.03 g, 7.47 mmoι)and the mixture was stirred for one and a half hours whereafter the cooling-bath was removed. The mixture was stirred for another two hours and then neutralized with 1% ΗC1. Water (100 mL) was added and the mixture was extracted with CΗ2CI2 (50 mL x 3). The extracts were combined, washed with water (100 mL x 2), dried with magnesium sulphate, filtered and evaporated. The crude product (3.41 g) was used without further purification. 1H NMR (400 MHz, CDC13): δ 8.32 (d, J=2 Hz, 1H), 7.92-7.89 (m, 3H), 7.83 (bs, 1H), 7.72 (dd, J =9, 2 Hz, 1H), 7.49-7.47 (m, 3H), 4.71 (s, 2H), 1.52 (s, 9H).
Examples
Example 1 l-(2-Methoxyethyl)-3-[(4-methosyphenyl)anιino]-4-phenyl-lH-pyrrole-2,5-dione
3-Chloro-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione (0.20 mmol, 53 mg) and 4- methoxyaniline (0.48 mmol, 59 mg) were dissolved in DMF (1 mL). The mixture was heated in a microwave reactor at 150°C for five min.min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN — > 100% CH3CN) to give 15 mg (21%) of the title compound. 1H NMR (400 MHz, CDC13): δ 7.27 (bs, 1H), 7.13-7.04 (m, 3H), 7.00-6.96 (m, 2H), 6.61-6.50 (m, 4H), 3.80 (t, J=5.6 Hz, 2H), 3.67 (s, 3H), 3.62 (t, J=5.6 Hz, 2H), 3.36 (s, 3H). Example 2
3-{[4-(Difluoromethoxy)phenyl]amino}-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5- dione
3-Chloro-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione (0.13 mmol, 36 mg) and 4- difluoromethoxyaniline (0.28 mmol, 45 mg) were dissolved in DMF (1 mL). The mixture was heated in a microwave reactor at 150°C for 20 min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN —> 100% CH3CN) to give 13 mg (24%) of the title compound. 1H NMR (400 MHz, CDC13): δ 7.25 (bs, IH), 7.19-7.08 (m, 3H), 7.02-6.97 (m, 2H), 6.81-6.75 (m, 2H), 6.66-6.60 (m, 2H), 6.36 (t, J=74.0 Hz, IH), 3.83 (t, J=5.7 Hz, 2H), 3.63 (t, J=5.7 Hz, 2H), 3.38 (s, 3H)
Example 3
N-(4-{[2,5-Dihydro-l-(2-methoxyethyl)-2,5-dioxo-4-phenyl-lH-pyrrol-3- yl]amino}phenyl)-acetamide 3-Chloro-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione (0.26 mmol, 70 mg) and 4- aminoacetanilide (0.53 mmol, 79 mg) was dissolved in dry CH3CN (2 mL) and the reaction mixture was subjected twice to microwave heating single node 140°C for 10 min.. 0.3 mL Water was added and the reaction mixture was purified using HPLC (57% 0.1M ammonium acetate buffer: 43% CH3CN — > 100% CH3CN, 20 mL/min) to give 45 mg (45%) of the title compound. 1H NMR (400 MHz, CD3CN) δ 8.17 (bs, IH), 7.78 (bs, IH), 7.24-7.09 (m, 5H), 7.04-7.00 (m, 2H), 6.73-6.68 (m, 2H), 3.73 (t, J=5.7 Hz, 2H), 3.59 (t, J=5.7 Hz, 2H), 3.33 (s, 3H), 2.01 (s, 3H).
Example 4 l-(2-Methosyethyl)-3-{[4(methylthio)phenyI]ainino}-4-phenyl-lB[-pyrroIe-2.5-dione
3-Chloro-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione (0.26 mmol, 70 mg) and 4- (methylthio)aniline (0.53 mmol, 73 mg) was dissolved in dry CH3CN (2 mL) and the reaction mixture was sequentially subjected to microwave heating single node 140°C for. 10 min, 140°C for 10 min, and 140°C for 20 min. 0.3 mL Water was added and the reaction mixture was purified using HPLC (57% 0.1M ammonium acetate buffer: 43% CH3CN → 100% CH3CN, 20 mL/min) to give 49 mg (50%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.22 (bs, IH), 7.19-7.10 (m, 3H), 7.06-7.00 (m, 2H), 6.95-6.90 (m, 2H), 6.58-6.53 (m, 2H), 3.82 (t, J=5.6 Hz, 2H), 3.63 (t, J=5.6 Hz, 2H), 3.38 (s, 3H), 2.38 (s, 3H).
Example 5
3-[(2-Acetyl-5-benzofuranyl)amino]-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5- dione
3-Chloro-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione (0.26 mmol, 70 mg) and 1- (5~aminobenzo[b]furan-2-yl)ethan-l-one (0.53 mmol, 92 mg) was dissolved in dry CH3CN (2 mL) and the reaction mixture was subjected to microwave heating single node 150°C for 15 min and purified on SiO2 (EtOAc:heptane, 1:1) to give 18 mg (15%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.53 (bs, IH), 7.40 (d, IH), 7.24-7.09 (m, 5H), 7.06 (dd, IH), 6.92 (d, IH), 3.98 (t, J=5.6 Hz, 2H), 3.78 (t, J=5.6 Hz, 2H), 3.52 (s, 3H), 2.69 (s, 3H).
Example 6 l-(2-Methoxyethyϊ)-3-[(4-morphoϊin-4-ylphenyl)amino]-4-phenyI-lH-pyrrole-2.5- dione
3-Chloro-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione (0.26 mmol, 70 mg) and 4- morpholinoaniline (0.53 mmol, 94 mg) was dissolved in dry CH3CN (2 mL) and the reaction mixture was subjected to microwave heating single node 130°C for 10 min and purified on SiO2 (EtOAc:heptane, 1:1) to give 96 mg (89%) of the title compound. 1H NMR (400 MHz, CD3CN) δ 7.73 (bs, IH), 7.17-7.04 (m, 3H), 6.98-6.93 (m, 2H), 6.70- 6.64 (m, 2H), 6.59-6.54 (m, 2H), 3.75-3.70 (m, 6H), 3.58 (t, J=5.6 Hz, 2H), 3.33 (s, 3H), 2.98-2.95 (m, 4H).
Example 7
3-[(4-Morpholin-4-ylphenyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione 4-Morpholinoaniline (0.94 mmol, 178 mg) dissolved in dry CH3CN (2 mL) was added to crude 3-chloiO-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyιτole-2,5-dione (0.47 mmol, 140 mg) and the reaction mixture was subjected to microwave heating single node 130°C for 10 min. 0.3 mL water was added and the reaction mixture was purified using HPLC (57% 0.1M ammonium acetate buffer: 43% CH3CN → 100% CH3CN, 20 mL/min) to give 56 mg (27%) of the title compound. 1H NMR (400 MHz, CD3CN) δ 8.63 (d, IH), 8.51 (dd, IH), 7.81-7.73 (m, IH), 7.36-7.31 (m, IH), 7.16-7.11 (m,lH), 7.10-7.04 (m, 2H), 6.99- 6.93 (m, 2H), 6.69-6.64 (m, 2H), 6.59-6.53 (m, 2H), 4.75 (s, 2H), 3.74 (t, 1=4.8 Hz, 4H), 2.97 (t, 1=4.8 Hz, 4H).
Example 8 3-[(2-Acetyl-5-benzofuranyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione l-(5-Aminobenzo[b]furan-2-yl)ethan-l-one (0.94 mmol, 164 mg) dissolved in dry CH3CN (2 mL) was added to crude 3-chloro-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione (0.47 mmol, 140 mg) and the reaction mixture was subjected to microwave heating single node 130°C for 10 min. 0.3 mL water was added and the reaction mixture was purified using HPLC (57% 0.1M ammonium acetate buffer: 43% CH3CN — > 100% CH3CN, 20 mL/min) to give 15 mg (7%) of the title compound. 1H NMR (400 MHz, CD3CN) δ 8.64 (d, IH), 8.52 (dd, IH), 8.01 (bs, IH), 7.80-7.75 (m, IH), 7.35 (dd, IH), 7.31-7.23 (m, 2H), 7.08-6.93 (m, 7H), 4.77 (s, 2H), 2.50 (s, 3H).
Example 9
3-Phenyl-l-(pyridin-3-ylmethyl)-4-{[4-(trifluoromethoxy)phenyl]amino}-lH-pyrrole-
2,5-dione
4-(Trifluoromethoxy)aniline (0.94 mmol, 177 mg) dissolved in dry CH3CN (2 mL) was added to crude 3-chloro-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5-dione (0.47 mmol, 140 mg) and the reaction mixture was sequentially subjected to microwave heating single node 140°C for 20 min, 140°C for 120 min, and 140°C for 120 min. 0.3 mL Water was added and the reaction mixture was purified using HPLC (57% 0.1M ammonium acetate buffer: 43% CH3CN → 100% CH3CN, 20 mL/min) to give 92 mg (45%) of the title compound. 1H NMR (400 MHz, CD3CN) δ 8.63 (d, IH), 8.52 (dd, IH), 7.95 (bs, IH), 7.80-7.74 (m, IH), 7.37-7.32 (m, IH), 7.19-7.08 (m, 3H), 7.01-6.95 (m, 2H), 6.94-6.88 (m, 2H), 6.84-7.78 (m, 2H), 4.77 (s, 2H). Example 10 3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-3-ylmethyI)-lH-pyrrole-2,5-dione
To a solution of 3-chloro-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5-dione (0.50 mmol, 149 mg) in DMF (1 mL) was added 4-methoxyaniline (1.10 mmol, 135 mg) The mixture was heated in a microwave reactor at 150°C for five min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 77 mg (40%) of the title compound. 1H NMR (400 MHz, CDC13) δ 8.71 (d, J=1.8 Hz, IH), 8.54 (dd, J,=4.7 Hz, J2=1.6 Hz, IH), 7.80-7.75 (m, IH), 7.35 (bs, IH), 7.26 (dd, It=7.8 Hz, J2=4.7 Hz, IH), 7.15-7.05 (m, 3H), 6.98-6.94 (m, 2H), 6.62-6.50 (m, 4H), 4.78 (s, 2H), 3.68 (s, 3H).
Example 11 3-Anilino-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5-dione To a solution of 3-chloro-4-phenyl- 1 -(pyridin-3-ylmethyl)- 1 H-pyrrole-2,5-dione (0.25 mmol, 75 mg) in DMF (0.5 mL) was added aniline (0.55 mmol, 51 mg). The mixture was heated in a microwave reactor at 150°C for five min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN -» 100% CH3CN) to give 38 mg (43%) of the title compound. 1H NMR (400 MHz, CDC13) δ 8.72 (bs, IH), 8.54 (d, br, IH), 7.79-7.75 (m, IH), 7.47 (bs, IH), 7.29-7.23 (m, IH), 7.17-7.06 (m, 3H), 7.04-6.93 (m, 5H), 6.66-6.60 (m, 2H), 4.79 (s, 2H).
Example 12 3-{[4-(Difluoromethoxy)phenyl]amino}-4-phenyl-l-(pyridin-3-ylmethyl)-IH-pyrrole- 2j5-dione
4-(Difluoromethoxy)aniline (0.94 mmol, 149 mg) dissolved in dry CH3CN (2.3 mL) was added to crude 3-chloro-4-phenyI-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5-dione (0.39 mmol, 115 mg) and the reaction mixture was subjected to microwave heating single node 140°C, one h. The reaction mixture was purified using HPLC (57% 0.1M ammonium acetate buffer: 43% CH3CN → 100% CH3CN, 20 mL/min) to give 122 mg (75%) of the title compound. 1H NMR (400 MHz, CD3CN) δ 8.63 (d, IH), 8.51 (dd5lH), 7.92 (bs, IH), 7.79-7.74 (m, IH), 7.34 (dd, IH), 7.20-7.07 (m, 3H), 7.00-6.94 (m, 2H), 6.78 (s, 4H), 6.59 (t, J=74.1 Hz, IH), 4.76 (s, 2H).
Example 13 l-[4-(Dimethylamino)benzyl]-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5- dione
3-Chloro-l-[4-(dimethylamino)benzyl]-4-phenyl-lH-pyrrole-2,5-dione (0.20 mmol, 68 mg) and 4-methoxyaniline (0.48 mmol, 59 mg) were dissolved in DMF (1 mL). The mixture was heated in a microwave reactor at 150°C for five min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 11 mg (13%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.38-7.34 (m, 2H), 7.15 (bs, IH), 7.13-7.04 (m, 3H), 6.97 (m, 2H), 6.70 (d, 2H), 6.60- 6.51 (m, 4H), 4.67 (s, 2H), 3.69 (s, 3H), 2.93 (s, 6H).
Example 14
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyrϊdin-4-ylmethyl)-lH-pyrrole-255-dione A mixture of 3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione (0.50 mmol, 147 mg), 4-hydroxymethylpyridine (0.75 mmol, 82 mg), diethyl azodicarboxylate (0.75 mmol, 131 mg) and triphenylphosphine (0.75 mmol, 197 mg) in dry THF (2 mL) was heated in a microwave reactor at 120°C for five min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 56 mg (29%) of the title compound. 1H NMR (400 MHz, CDC13) δ 8.59 (bs, 2H), 7.35-7.29 (m, br, 2H), 7.25 (s, br, IH), 7.17-7.06 (m, 3H), 7.01-6.96 (m, 2H), 6.63-6.53 (m, 4H), 4.77 (s, 2H), 3.70 (s, 3H).
Example 15 3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-2-ylmethyl)-lH-pyrrole-2,5-dione
3-Chloro-4-phenyl-l-(pyridin-2-ylmethyl)-lH-pyrrole-2,5-dione (2.39 mmol, 714 mg) and 4-methoxyaniline (5.26 mmol, 648 mg) were dissolved in DMF (4 mL). The mixture was heated in a microwave reactor at 150°C for five min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN — > 100% CH3CN) to give 710 mg (77%) of the title compound. . 1H NMR (400 MHz, CDC13): 8.60- 8.57 (m, IH), 7.71-7.65 (m, IH), 7.36-7.30 (m, IH), 7.24 (bs, IH), 7.23-7.19 (m, IH), 7.13-7.05 (m, 3H), 7.04-6.99 (m, 2H), 6.64-6.53 (m, 4H), 4.95 (s, 2H), 3.70 (s, 3H).
Example 16 3-[(4-Methoxyphenyl)amino]-l-(3-methoxypropyl)-4-phenyl-lH-pyrrole-2,5-dione 3-Chloro-l-(3-methoxypropyl)-4-phenyl-lH-pyrrole-2,5-dione (0.20 mmol, 56 mg) and 4- methoxyaniline (0.48 mmol, 59 mg) were dissolved in DMF (1 mL). The mixture was heated in a microwave reactor at 150°C for five min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 11 mg ( 15%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.17 (bs, IH), 7.14-7.05 (m, 3H), 7.01-6.95 (m, 2H), 6.63-6.52 (m, 4H), 3.71 (t, J=7.0 Hz, 2H), 3.70 (s, 3H), 3.45 (t, J=6.2 Hz, 2H), 3.34 (s, 3H), 1.94 (m, 2H).
Example 17 Methyl 4-({3-[(4-methoxyphenyl)amino]-255-dioxo-4-phenyl-2.5-dihydro-lH-pyrrol-l- yl}nιethyl)bensoate
Methyl 4-[(3-chloro-2,5-dioxo-4~phenyl-2,5-dihydro- lH-pyrrol- l-yl)methyl]benzoate (0.24 mmol, 85 mg), 4-methoxyaniline (0.26 mmol, 33 mg) and triethylamine (0.29 mmol, 29 mg) were dissolved in DMF (1 mL). The mixture was heated in a microwave reactor at 150°C for five min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 32 mg (30%) of the title compound. 1H NMR (400 MHz, CDC13) δ 8.03-7.99 (m, 2H), 7.52-7.46 (m, 2H), 7.21 (bs, IH), 7.16-7.05 (m, 3H), 7.01-6.95 (m, 2H), 6.62-6.52 (m, 4H), 4.81 (s, 2H), 3.90 (s, 3H), 3.69 (s, 3H).
Example 18 3-[(4-Methoxyphenyl)amino]-l-[2-(methyIthio)ethyl]-4-phenyl-lH-pyrrole-2,5-dione
3-Chloro-l-[2-(methylthio)ethyl]-4-phenyl-lH-pyrrole-2,5-dione (0.40 mmol, 113 mg) and 4-methoxyaniline (0.88 mmol, 109 mg) were dissolved in DMF (1 mL). The mixture was heated in a microwave reactor at 150°C for 10 min.. After cooling, the solvent was evaporated under reduced pressure. The residue was partitioned between water and CH2C12. The organic phase was evaporated and purified by flash chromatography using a pre-packed silica column. The desired product was eluted with heptane/EtOAc 2: 1. Yield 118 mg (80%).1H NMR (400 MHz, CDC13) δ 7.26 (bs, IH), 7.15-7.06 (m, 3H), 7.01-6.96 (m, 2H), 6.63-6.52 (m, 4H), 3.83 (t, J=7.0 Hz, 2H), 3.69 (s, 3H), 2.79 (t, J=7.0 Hz, 2H), 2.18 (s, 3H). 5 Example 19 3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(3,3,3-tri luoropropyl)-lH-pyrrole-2,5-dione To a solution of 3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione (0.17 mmol, 50 mg), 3,3,3-trifluoropropan-l-ol (0.19 mmol, 21 mg), diethyl azodicarboxylate (0.19 ic mmol, 33 mg) in dry THF (1 mL) was added triphenylphosphine (0.19 mmol, 49 mg) in dry THF (1 mL). The mixture was heated in a microwave reactor at 130°C for six min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 51 mg (77%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.27 (bs, IH), 7.17-7.06 (m, 3H), 7.00-6.95 (m, 2H), 6.64-6.55 is (m, 4H), 3.89 (t, J=7.3 Hz, 2H), 3.70 (s, 3H), 2.61-2.48 (m, 2H).
Example 20 l-(3-Fuι^lmethyl)-3-[(4-methosyphenyl)amino]-4-phenyl-lH-pyrrole-2,S-dione To a solution of 3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione (0.17 mmol, 20 50 mg), 3-furanmethanol (0.19 mmol, 18 mg), diethyl azodicarboxylate (0.19 mmol, 33 mg) in dry THF (1 mL) was added triphenylphosphine (0.19 mmol, 49 mg) in dry THF (1 mL). The mixture was heated in a microwave reactor at 130°C for six min.. After cooling, the reaction mixture was purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 17 mg (27%) of the title compound. 1H NMR (400 25 MHz, CDC13) δ 7.61 (bs, IH), 7.35 (bs, IH), 7.16 (bs, IH), 7.15-7.05 (m, 3H), 7.00-6.95 (m, 2H), 6.62-6.51 (m, 4H), 6.48 (bs, IH), 4.63 (s, 2H), 3.69 (s, 3H).
Example 21 3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(2,2,2-trifluoroethyl)-lH-pyrrole-2,5-dione
30 A solution of 3-[(4-methoxyphenyl)amino]-4~phenyl~lH-pyrrole-2,5-dione (2.11 mmol, 620 mg), diethyl azodicarboxylate (2.11 mmol, 367 mg) and triphenylphosphine (2.11 mmol, 553 mg) in dry THF (2 mL) was prepared in sealed reaction vessel. 2,2,2- trifluoroethanol (2.11 mmol, 211 mg) was added. The mixture was stirred at 40°C for 19 hours. Acetonitrile was added until some triphenylphosphine oxide was precipitated. The reaction mixture was filtered and purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 260 mg (33%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.30 (bs, IH), 7.18-7.06 (m, 3H), 7.01-6.96 (m, 2H), 6.64-6.52 (m, 4H), 4.23 (q, 1=8.8 Hz, 2H), 3.70 (s, 3H).
Example 22 3-[(4-Methoxyphenyl)amino]-l-[(5-methylisoxazol-3-yl)methyl]-4-phenyl-lH-pyrrole- 2,5-dione
To a solution of 3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione (0.17 mmol, 50 mg), 5-methylisoxazole-3-methanol (0.19 mmol, 21 mg) and diethyl azodicarboxylate (0.19 mmol, 33 mg) in dry THF (1 mL) was added triphenylphosphine (0.19 mmol, 49 mg) in dry THF (1 mL). The mixture was heated in a microwave reactor at 130°C for six min.. After cooling, the reaction mixture was purified by HPLC (95% 0. IM ammonium acetate buffer: 5% CH3CN - 100% CH3CN) to give 14 mg (21%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.23 (bs, IH), 7.16-7.06 (m, 3H), 7.01-6.96 (m, 2H), 6.63-6.53 (m, 4H), 6.03 (d, 1=0.7 Hz, IH), 4.82 (s, 2H), 3.70 (s, 3H), 2.39 (d, J=0.7 Hz, 3H).
Example 23
Ethyl {3-[(4-methoxyphenyl)amino]-2,5-dioxo-4-phenyl-25S-dihydro-liH'-pyrrol-l- yljacetate
To a solution of 3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione (0.34 mmol,
100 mg) in dry THF (1.0 mL) under an atmosphere of N2 at room temperature was added ethyl glycolate (0.34 mmol, 35 mg). The reaction mixture was cooled to 0°C and tributylphosphine (0.17 mmol, 34 mg) was added followed by 1,1'- (azodicarbonyl)dipiperidine (0.36 mmol, 84 mg). After stirring at 0°C for 10 min., the reaction mixture was brought to room temperature and the stirring was continued for 26 h. The reaction mixture was diluted with CH3CN: water 1:1 (2 mL) and purified using HPLC (95% 0. IM ammonium acetate buffer:5% CH3CN → 100% CH3CN, 38.5 min., 25 mL/min.) to give 53 mg (41%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.22- 7.17 (bs, IH), 7.15-7.05 (m, 3H), 7.01-6.96 (m, 2H), 6.63-6.52 (m, 4H), 4.36 (s, 2H), 4.24 (q, J=7.1 Hz, 2H), 3.69 (s, 3H), 1.30 (t, J=7.1 Hz, 3H).
Example 24 3-Phenyl-l-(2,2,2-trifluoroethyl)-4-{[4-(trifluoromethoxy)phenyl]amino}-lH-pyrrole- 2,5-dione
A mixture of 3-phenyl-4-{ [4-(trifluoromethoxy)phenyl]amino}-lH-pyrrole-2,5-dione (0.63 mmol, 220 mg), diethyl azodicarboxylate (0.70 mmol, 121 mg) and triphenylphosphine (0.70 mmol, 182 mg) in dry THF (4 mL) was prepared in sealed reaction vessel. 2,2,2-Trifluoroethanol (0.70 mmol, 70 mg) was added. The mixture was first stirred at rt. for three days, then at 40°C for two hours and finally at 100°C for 30 min. in a microwave reactor. The reaction mixture was filtered and purified by HPLC (95% 0.1M ammonium acetate buffer: 5% CH3CN → 100% CH3CN) to give 7 mg (3%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.45 (s, br, IH), 7.22-7.09 (m, 3H), 7.02- 6.97 (m, 2H), 6.92-6.84 (m, 2H), 6.70-6.65 (m, 2H), 4.24 (q, J=8.6 Hz, 2H).
Example 25 l-[(β-Amϊnopyridin-3-yl)methyl]-3-[(4-methoxyphenyl)amino]-4-phenyl-lH'-pyrrole-
2,5-dione To a solution of tert-butyl {5-[(3-chloro-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyrrol-l- yl)methyl]pyridin-2-yl}carbamate (0.86 mmol, 357 mg) in dry DMF (1.0 mL) was added 4-methoxyaniline (0.96 mmol, 118 mg) and anhydrous potassium carbonate (0.96 mmol, 133 mg) and the reaction mixture was subjected to microwave heating single node at 150°C for 15 min. The reaction mixture was purified using ΗPLC (95% 0.1M ammonium acetate buffer:5% CΗ3CN — > 5% 0.1M ammonium acetate buffer: 95% CH3CN, 10 min., 25 mL/min.) to give 102 mg (29%) of the title compound. 1H NMR (400 MHz, CDC13) δ 8.03 (s, IH), 7.62 (dd, J=8.6 Hz, J=2.3 Hz, IH), 7.21 (bs, IH), 7.15-7.04 (m, 3H), 6.98- 6.93 (m, 2H), 6.62-6.49 (m, 5H), 4.62 (s, 2H), 3.69 (s, 3H).
Example 26 l-[(6-AminopyridiE-3-yl)methyl]-3-{[4-(iiflιιoromethosy)phenyl]amiιιo}-4-p!ιeϊiyl- lff-pyrrole-2,5-dione A mixture of tert-butyl {5-[(3-chloro-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyrrol-l- yl)methyl]pyridin-2-yl}carbamate ( 0.70 g, 1.7 mmol) and 4-(difluoromethoxy)-aniline (0.54 g, 3.4 mmol) in DMF (4 mL) was heated in a microwave reactor at 150°C for eight min.. The sovent was evaporated and the residue was purified on a column (Isolute® SI, 10g/70 mL), using CΗ2C12 and then CH3OH/ CH2C12 (1 :99, 2:98 and then 5:95) as eluant, to give 0.4 g (54%) of the title compound. 1H NMR (400 MHz, CDC13) δ 7.99 (bs, IH), 7.67-7.62 (m, 2H), 7.14-7.04 (m, 3H), 6.91 (d, J =8 Hz, 2H), 6.78 (d, J=8 Hz, IH), 6.72 (d, J=9 Hz, 2H), 6.63 (d, J=9 Hz, 2H), 6.33 (t, J=74 Hz, IH), 4.60 (s, 2H).
Example 27 l-[(6-Aminopyridin-3-yl)methyl]-3-[(4-morpholin-4-ylphenyl)amino]-4-phenyl-lJHr- pyrrole-2,5-dione
A mixture of tert-Butyl {5-[(3-chloro-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyιτol-l- yl)methyl]pyridin-2-yl}carbamate ( 0.85 g, 2.06 mmol ) and 4-morpholinoaniline (0.73 g, 4.12 mmol) in DMF (4 mL) was heated in a microwave reactor at 150°C for 10 min.. Preparative ΗPLC (C18, 50x250 mm, 60% 0.1M ammonium acetate buffer:40% CΗ3CN → 100% CH3CN) gave 0.39 g (42%) of the title compound. 1H NMR (400 MHz, CDC13) δ 8.14 (bs, IH), 7.55 (dd, J= 8, 2 Hz, 1H)? 7.28-7.23 (br, IH), 7.13-7.04 (m, 3H), 6.95 (dd, J = 8, 2 Hz, 2H), 6.57-6.51 (m, 4H), 6.44 (d, J= 8 Hz, IH), 4.62 (s, 2H), 4.62-4.53 (br, 2H), 3.81-3.79 (m, 4H), 3.01-2.98 (m, 4H).
BIOLOGICAL ACTIVITY
CO-ACTIVATOR RECRUITMENT ASSAY The Ligand Binding Domain (LBD) of human LXRalpha (amino acid 205-447) and LXRbeta (amino acid 216-461) was produced by recombinant techniques in E coli. A fragment of the human Steroid Receptor Co- Activator- 1 (SRC-1) was produced as a synthetic peptide. An anti-6His-antibody coupled with Europium (Eu3+) was used to recognize the His-tag on the LXR-LBD and Allophycocyanin (APC) coupled to streptavidin was used to recognize the biotinylated SRC-1. Agonist binding to LXRalpha or LXRbeta enhances the affinity of LXR towards SRC-1 and thereby brings Eu and APC in close proximity. Eu3+ is excited at 337 nm and emitts light at 620 nm. This emission, when in close proximity, excites APC to emit light at 665 nm.
Dilution plates with compounds in DMSO were further diluted in buffer {20mM [Tris(hydroxymethyl)aminomethane] pH 7.5, 0.125% CHAPS { 3-[(3-
Cholamidopropyl)dimethylammonio]-l-propanesulfonate}, 2mM DTT (Dithiothreitol) and 0.05% BSA (Bovine Serum Albumin)} in order to reduce DMSO concentration, 0.5 μl to 13.5 μl. To this, 6 μl assay mix was added and the plates (384-well N-groove plates) were incubated at room temperature for 60 to 80 min.. The assay mix has the following final concentrations; LXRalpha mix: 0.06 μg/mL Eu-labelled anti-6x His Ab, 1.15μg/mL
Streptavidin APC, 30 nM SRC-1 peptide and 0.9 μg/mL LXRalpha in buffer and LXRbeta mix; 0.06 μg/mL Eu-labelled anti-6x His Ab, 1.15μg/mL Streptavidin APC, 90 nM SRC-1 peptide and 0.2 μg/mL LXRbeta in buffer. Time-resolved fluorescence readings were done in a Wallac Victor reader at 665 nm followed by reading at 615 nm. The LXR ligand, 22-R Hydroxycholesterol at 50μM was used as the 100% control.
TRAΝSACTΓVATIOΝ ASSAY
Expression vectors were prepared by inserting the ligand binding domain cDΝA (complementary DΝA) of human LXRalpha (amino acid 205-447) and LXRbeta (amino acid 216-461) in frame with, 3' to the yeast GAL4 transcription factor DΝA binding domain and the nuclear localization signal from the T-antigen of Polyoma Virus in the eucaryotic expression vector pSG5 (Stratagene) . The resulting expression vectors pSGGAL-LXRalpha and pSGGAL-LXRbeta were used in cotransfection experiments together with the pGL3 luciferase reporter plasmid containing a minimal SN40 promoter and five copies of the UAS GAL4 recognition site. 2.5 μg pSGGAL-LXRalpha or beta were mixed with 25 μg pGL3 5xUAS and 22.5 μg pBluscript in 0.95 mL ice cold PBS containing approx. 4-9 milj. U2/OS osteosarcoma cells. After a five minute incubation on ice the cell/DΝA mixture was electroporated in 0.4 cm cuvettes at 960 μF, 230 N using a BioRad electroporator and diluted to 0.32 milj cells /mL in complete DMEM (Dulbecco's Modified Eagle Medium) medium (Gibco 31966-021). Cells from at least two electroporations were pooled in order to avoid variations between different electroportations. 25 μl diluted, electroporated cells, were seeded onto 384-well plates (0.8 x 104 cells/well) and the cells were allowed to adhere for 2 h at 37°C, 5% CO2 in a cell culture incubator. Dilution plates with compounds in DMSO were further diluted in DMEM w/o phenol red (Gibco 11880-028) including 10% FBS (Foetal Bovine Serum), 1% PEST (Penicillin Streptomycin), 20mM Hepes, 2mM L-Glutamine and 0.36% Glucose (2.5 μl to 97.5 μl) in order to reduce DMSO concentration. 7 μl of this was added to the electroporated cells in 384-well plates and incubation was continued for 48 h in a cell culture incubator, after which cells were lysed by adding 32 μl/well LucLite luciferase substrate. Luciferase activity was measured using the "Luminescence 384 protocol" in the Wallac Victor reader after 15 min. incubation at room temperature. The LXR ligand, Tularik T0901317, at lμM was used as the 100% control.
The compounds of formula I have an EC50 of less than 50 μmol/1 for LXRalpha and/or beta in coactivator recruitment assays and/or reporter gene assays. For example, the compounds of Examples 13 and 22 were EC50's of 0.15 μmol 1 and 0.11 μmol/1 in coactivator recruitment assays, respectively.
In addition the compounds of the present invention exhibit improved physical and/or chemical and/or DMPK (Drug Metabolism and Pharmacokinetic) properties, for example they exhibit improved metabolic stability in vitro, and/or exhibit favourable pharmacological effects in vivo. The compounds also have a promising toxicological profile.

Claims

1. A compound of Formula I:
Figure imgf000053_0001
Formula I wherein R1 is selected from phenyl(l-4C)alkyl wherein the phenyl is substituted by (1- 4C)alkoxycarbonyl or a group of formula NRaRb in which Ra and Rb independently represent H or (l-4C)alkyl; heteroaryl(l-4C)alkyl wherein the heteroaryl optionally is substituted by (l-4C)alkyl or a group of formula NRaRb in which Ra and Rb independently represent H or (l-4C)alkyl; or a (l-4C)alkyl group which is substituted by one or more of the following: fluoro, (l-4C)alkoxycarbonyl, (l-3C)alkylthio or (l-3C)alkoxy optionally substituted by one or more fluoro; R2 is phenyl;
R3 is selected from phenyl, indolyl or benzofuranyl each optionally substituted by one or more of the following: (l-3C)alkanoyl, (l-3C)alkoxy optionally substituted by one or more fluoro; (l-3C)alkylthio; or a group of formula NRaRb in which Ra and Rb independently represent H, (l-3C)alkyl or (l-3C)alkanoyl or R and Rb together with the nitrogen atom to which they are attached represent morpholino? or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.
2. A compound according to claim 1 in which M1 is selected from 2-methoxyethyl, 2- methylthioethyl, 2,2,2-trifluoroethyl, 3-mefhoxypropyl, 3,3,3-trifluoropropyl, ethoxycarbonylmethyl, 4-N,N-dimethylaminobenzyl, 4- methoxycarbonylbenzyl, 2- pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 6-amino-3-pyridylmethyl, 3-furylmethyl or (5-methylisoxazol-3yl)methyl.
3. A compound according to either claim 1 or claim 2 in which R3 is selected from phenyl, 4-methoxyphenyl, 4-methylthiophenyl, 4-morpholinophenyl, 4-acetylaminophenyl, 4-trifluoromethoxyphenyl, 4-difluoromethoxyphenyl or 2-acetyl-5-benzofuranyl.
4. A compound according to claim 1 in which R1 is selected from 2-methoxyethyl, 2,2,2- trifluoroethyl, 3,3,3-trifluoropropyl, 3-methoxypropyl, ethoxycarbonylmethyl, 2- pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 6-amino-3-pyridylmethyl or (5- methylisoxazol-3yl)methyl; R2 is phenyl; R3 is selected from phenyl, 4-methoxyphenyl, 4-acetylaminophenyl, 4- difluoromethoxyphenyl or 4-morpholinophenyl.
5. A compound according to claim 1 in which R1 is selected from 2-methoxyethyl, 6- amino-3-pyridylmethyl, 3-pyridylmethyl or 2,2,2-trifluoroethyl; R2 is phenyl; and
R3 is selected from 4-methoxyphenyl, 4-difluoromethoxyphenyl, 4- trifluoromethoxyphenyl or 4-morpholinophenyl.
6. A compound according to claim 1 in which R1 is selected from 2,2,2-trifluoroethyl, 3- furylmethyl, 6-amino-3-pyridylmethyl or 3-pyridylmethyl;
R2 is phenyl; and
BL3 is selected from 4-methoxyphenyl , 4-difluoromethoxyphenyl, 4-morpholinophenyl or
2-acety 1-5 -benzofuranyl .
7. A compound according to claim 1 in which R1 is selected from 6-amino-3- pyridylmethyl or 2-methoxyethyl; R is phenyl; and
R3 is selected from 4-morpholinophenyl, 4-trifluoromethoxyphenyl or 4- difluoromethoxyphenyl.
8. A compound according to claim 1 in which M, is selected from 6-amino-3- pyridylmethyl, 3-furylmethyl, 3-pyridylmethyl, 2,2,2-trifluoroethyl or 2-methoxyethyl; R2 is phenyl; and
R3 is selected from 4-morpholinophenyl, 4-methoxyphenyl, 4-trifluoromethoxyphenyl, 4- difluoromethoxyphenyl or 2-acetyl-5-benzofuranyl.
9. A compound selected from one or more of the following: l-(2-Methoxyethyl)-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione
3- { [4-(Difluoromethoxy)phenyl] amino } - 1 -(2-methoxyethyl)-4-phenyl- lH-pyrrole-2,5- dione
N-(4- { [2,5-Dihydro- 1 -(2-methoxyethyl)-2,5-dioxo-4-phenyl- 1 H-pyrrol-3- yl]amino}phenyl)-acetamide
1 -(2-Methoxyethyl)-3- { [4(methylthio)phenyl] amino } -4-phenyl- 1 H-pyrrole-2,5-dione 3-[(2-Acetyl-5-benzofuranyl)amino]-l-(2-methoxyethyl)-4-phenyl-lH-pyrrole-2,5-dione l-(2-Methoxyethyl)-3-[(4-morpholin-4-ylphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione 3-[(4-Morpholin-4-ylphenyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione
3-[(2-Acetyl-5-benzofuranyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione
3-Phenyl- 1 -(pyridin-3-ylmethyl)-4- { [4-(trifluoromethoxy)phenyl] amino } - 1 H-pyrrole-2,5- dione 3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5-dione 3-Anilino-4-phenyl- 1 -(pyridin-3-ylmethyl)- lH-pyrrole-2,5-dione 3-[[4-(Difluoromethoxy)phenyl]amino]-4-phenyl-l-(pyridin-3-ylmethyl)-lH-pyrrole-2,5- dione l-[4-(Dimethylamino)benzyl]-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5- dione
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-4-ylmethyl)-lH-pyrrole-2,5-dione 3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(pyridin-2-ylmethyl)-lH-pyrrole-2s5-dione 3-[(4-Methoxyphenyl)amino]-l-(3-methoxypropyl)-4-phenyl-lH-pyrrole-2,5-dione Methyl 4-({3-[(4-methoxyphenyl)amino]-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyrrol-l- yl } methyl)benzoate
3-[(4-Methoxyphenyl)amino]-l-[2-(methylllιio)ethyl]-4-phenyl-lH-pyrrole-2,5-dione 3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(3,3,3-trifluoropropyl)-lH-pyrrole-2,5-dione l-(3-Furylmethyl)-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5-dione
3-[(4-Methoxyphenyl)amino]-4-phenyl-l-(2,2,2-trifluoroethyl)-lH-pyrrole-2,5-dione
3-[(4-Methoxyphenyl)amino]-l-[(5-methylisoxazol-3-yl)methyl]-4-phenyl-lH-pyrrole-2,5- dione Ethyl {3-[(4-methoxyphenyl)amino]-2,5-dioxo-4-phenyl-2,5-dihydro-lH-pyrrol-l- yl} acetate
3-Phenyl-l-(2,2,2-trifluoroethyl)-4-{[4-(trifluoromethoxy)phenyl]amino}-lΗ-pyrrole-2,5- dione l-[(6-Aminopyridin-3-yl)methyl]-3-[(4-methoxyphenyl)amino]-4-phenyl-lH-pyrrole-2,5- dione
1 - [(6- Aminopyridin-3 -yl)methyl] -3- { [4-(difluoromethoxy)phenyl] amino } -4-phenyl- 1H- pyrrole-2,5-dione and l-[(6-Aminopyridine-3-yl)methyl]-3-[(4-morpholin-4-ylρhenyl)amino]-4-phenyl-l-Η- pyrrole-2,5-dione or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.
10. A process for the preparation of a compound according to any one of claims 1-9, wherein Rls R2 and R3 are as defined in claim 1, comprising the step of reacting a compound of formula II,
Figure imgf000056_0001
wherein R2 and R3 are as defined in claim 1, with a compound of formula III, R QH (HI) wherein Ri is as defined in claim 1, in the presence of dialkyl azodicarboxylate, for example diethyl azodicarboxylate, and a phosphine, for example triphenylphosphine, optionally in the presence of an inert organic liquid, for example an ether such as tetrahydrofuran, at a temperature in the range of 0°C to 200°C.
11. A process for the preparation of a compound according to any one of claims 1-9, wherein Rls R2 and R3 are as defined in claim 1, comprising the step of reacting a compound of formula IV,
Figure imgf000057_0001
wherein Ri and R2 are as defined in claim 1 and Y is a leaving group such as for example halogen (CI, Br, I), with a compound of formula N, R3ΝH2 (V) wherein R3 is as defined in claim 1, optionally in the presence of an inert organic liquid, for example dimethylformamide, and optionally in the presence of a base, for example potassium carbonate, at a temperature in the range of 0°C to 250°C.
12. A pharmaceutical formulation comprising a compound according to any one of claims 1-9 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
13. The use of a compound according to any one of claims 1-9 in therapy.
14. The use of a compound according to any of claims 1-9 for the manufacture of a medicament for the modulation of the nuclear hormone receptors LXR α and/or β.
15. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of cardiovascular disease.
16. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of atherosclerosis.
17. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of hypercholesterolemia.
18. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for improving reverse cholesterol transport.
19. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for decreasing intestinal cholesterol absorption.
20. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for increasing HDL-cholesterol levels.
21. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with a need for decreasing LDL-cholesterol levels.
22. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of inflammatory conditions.
23. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of Alzheimer's disease.
24. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of arteriosclerosis.
25. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of type 2 diabetes.
26. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament the treatment and/or prophylaxis of conditions associated with a need for improving HDL function.
27. The use of a compound according to any one of claims 1-9 in the manufacture of a medicament for the treatment and/or prophylaxis of lipid disorders (dyslipidemia) whether or not associated with insulin resistance.
28. A method of treating and/or preventing lipid disorders (dyslipidemia) whether or not associated with insulin resistance comprising the administration of a compound according to any one of claims 1-9 to a mammal in need thereof.
29. A method for treatment and/or prophylaxis of cardiovascular disease comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
30. A method of treating and/or preventing atherosclerosis comprising the administration of an effective amount of a compound of formula I according to any one of claims 1-9 to a mammal in need thereof.
31. A method for treatment and/or prophylaxis of hypercholesterolemia comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
32. A method for treatment and/or prophylaxis of conditions associated with a need for improving reverse cholesterol transport comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
33. A method for treatment and/or prophylaxis of conditions associated with a need for decreasing intestinal cholesterol absorption comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
34. A method for treatment and/or prophylaxis of conditions associated with a need for increasing HDL-cholesterol levels comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
35. A method for treatment and/or prophylaxis of conditions associated with a need for decreasing LDL-cholesterol levels comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
36. A method for treatment and/or prophylaxis of inflammatory conditions comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
37. A method for treatment and/or prophylaxis of Alzheimer's disease comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
38. A method for treatment and/or prophylaxis of arteriosclerosis comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
39. A method for treatment and/or prophylaxis of type 2 diabetes comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
40. A method for treatment and/or prophylaxis of conditions associated with a need for improving HDL function comprising administering to a mammal, including man, in need of such a treatment an effective amount of a compound as defined in any of claims 1-9.
41. A pharmaceutical formulation for use in the treatment and/or prophylaxis of conditions associated with a need for modulation of the nuclear hormone receptors LXR α and/or β, comprising a compound according to any one of claims 1-9 as active ingredient in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
42. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 9 combined with another therapeutic agent that is useful in the treatment of conditions or disorders associated with the development and progress of atherosclerosis such as hypertension, dyslipidemias, hyperlipidaemias, hypercholesterolemias, type 2 diabetes, inflammation, obesity as well as conditions associated with a need for improving reverse cholesterol transport and/or decreasing intestinal cholesterol absorption.
PCT/SE2004/001114 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators WO2005005417A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE602004014773T DE602004014773D1 (en) 2003-07-11 2004-07-08 PYRROL-2,5-DION DERIVATIVES AS LIVER-X RECEPTOR MODULATORS
EP04749150A EP1646626B1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators
AU2004255999A AU2004255999B2 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver X receptor modulators
JP2006520138A JP2007521312A (en) 2003-07-11 2004-07-08 Pyrrole-2,5-dione derivatives as liver X receptor modulators
CA002532056A CA2532056A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators
MXPA06000414A MXPA06000414A (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators.
BRPI0412472-3A BRPI0412472A (en) 2003-07-11 2004-07-08 compound, process for preparing a compound, pharmaceutical formulation, use of a compound, methods of treating and / or preventing lipid disorders (dyslipidemia) associated or not with insulin resistance, and atherosclerosis, methods of treatment and / or prophylaxis of cardiovascular disease, hypercholesterolemia, conditions associated with the need to improve reverse cholesterol transport, and to decrease cholesterol absorption in the intestine, to increase HDL cholesterol levels, to lower cholesterol levels. ldl, inflammatory conditions, alzheimer's disease, type 2 diabetes arteriosclerosis, conditions associated with the need to improve hdl function, and pharmaceutical composition
US10/564,235 US7432288B2 (en) 2003-07-11 2004-07-08 Pyrrole-2,5-dione derivatives as Liver X receptor modulators
UAA200600272A UA82109C2 (en) 2003-07-11 2004-08-07 Pyrrole-2, 5-dione derivatives as liver x receptor modulators
IL172760A IL172760A0 (en) 2003-07-11 2005-12-22 Pyrrole-2,5-dithione derivatives as liver x receptor modulators
NO20060081A NO20060081L (en) 2003-07-11 2006-01-05 Pyrrole-2,5-dione derivatives supplying X receptor modulators
IS8293A IS8293A (en) 2003-07-11 2006-02-09 Pyrrole-2,5-dione derivatives that regulate liver receptor X
HK06108803.4A HK1088320A1 (en) 2003-07-11 2006-08-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
GB0316232.8 2003-07-11

Publications (1)

Publication Number Publication Date
WO2005005417A1 true WO2005005417A1 (en) 2005-01-20

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Country Status (26)

Country Link
US (1) US7432288B2 (en)
EP (1) EP1646626B1 (en)
JP (1) JP2007521312A (en)
KR (1) KR20060035748A (en)
CN (1) CN1823061A (en)
AR (1) AR045721A1 (en)
AT (1) ATE399777T1 (en)
AU (1) AU2004255999B2 (en)
BR (1) BRPI0412472A (en)
CA (1) CA2532056A1 (en)
DE (1) DE602004014773D1 (en)
ES (1) ES2308204T3 (en)
GB (1) GB0316232D0 (en)
HK (1) HK1088320A1 (en)
IL (1) IL172760A0 (en)
IS (1) IS8293A (en)
MX (1) MXPA06000414A (en)
MY (1) MY135821A (en)
NO (1) NO20060081L (en)
RU (1) RU2006102130A (en)
SA (1) SA04250204B1 (en)
TW (1) TW200503691A (en)
UA (1) UA82109C2 (en)
UY (1) UY28408A1 (en)
WO (1) WO2005005417A1 (en)
ZA (1) ZA200600222B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128458A1 (en) * 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
US7582629B2 (en) 2005-01-10 2009-09-01 Astrazeneca Ab Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
US7723333B2 (en) 2005-01-10 2010-05-25 Astrazeneca Ab Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
WO2012033353A2 (en) 2010-09-07 2012-03-15 서울대학교 산학협력단 Sesterterpene compounds and use thereof
WO2012074782A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators
WO2012074780A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
US8492427B2 (en) 2008-07-01 2013-07-23 Genentech, Inc. Isoindolones derivatives as MEK kinase inhibitors and methods of use
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
WO2017123568A2 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
CN101456863B (en) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Novel LXR agonist as well as preparation method and application thereof
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27510A (en) 1998-07-30 2001-04-12 Japan Tobacco Inc SUBSTITUTIONAL MALIMIDE COMPOUNDS AND PHARMACY USE
AU6593600A (en) 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582629B2 (en) 2005-01-10 2009-09-01 Astrazeneca Ab Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
US7723333B2 (en) 2005-01-10 2010-05-25 Astrazeneca Ab Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
US7960380B2 (en) 2005-01-10 2011-06-14 Astrazeneca Ab Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
WO2007128458A1 (en) * 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
US8492427B2 (en) 2008-07-01 2013-07-23 Genentech, Inc. Isoindolones derivatives as MEK kinase inhibitors and methods of use
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
WO2012033353A2 (en) 2010-09-07 2012-03-15 서울대학교 산학협력단 Sesterterpene compounds and use thereof
WO2012074782A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators
WO2012074780A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
US8518932B2 (en) 2010-12-03 2013-08-27 Allergan, Inc. Oxime azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
US8609636B2 (en) 2010-12-03 2013-12-17 Allergan, Inc. Oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
WO2017123568A2 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
US11459292B2 (en) 2019-12-13 2022-10-04 Inspirna, Inc. Metal salts and uses thereof
US11878956B2 (en) 2019-12-13 2024-01-23 Inspirna, Inc. Metal salts and uses thereof

Also Published As

Publication number Publication date
EP1646626B1 (en) 2008-07-02
IL172760A0 (en) 2006-04-10
UA82109C2 (en) 2008-03-11
IS8293A (en) 2006-02-09
EP1646626A1 (en) 2006-04-19
SA04250204B1 (en) 2008-03-23
AU2004255999A1 (en) 2005-01-20
BRPI0412472A (en) 2006-09-19
KR20060035748A (en) 2006-04-26
AR045721A1 (en) 2005-11-09
US7432288B2 (en) 2008-10-07
AU2004255999B2 (en) 2007-08-02
UY28408A1 (en) 2005-02-28
NO20060081L (en) 2006-02-08
JP2007521312A (en) 2007-08-02
MXPA06000414A (en) 2006-03-17
MY135821A (en) 2008-07-31
US20060235015A1 (en) 2006-10-19
CN1823061A (en) 2006-08-23
ZA200600222B (en) 2007-04-25
ES2308204T3 (en) 2008-12-01
CA2532056A1 (en) 2005-01-20
ATE399777T1 (en) 2008-07-15
RU2006102130A (en) 2007-08-20
HK1088320A1 (en) 2006-11-03
DE602004014773D1 (en) 2008-08-14
GB0316232D0 (en) 2003-08-13
TW200503691A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
US7432288B2 (en) Pyrrole-2,5-dione derivatives as Liver X receptor modulators
EP1646625B1 (en) Pyrrole-2, 5-dithione derivatives as liver x receptor modulators
US7960380B2 (en) Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
US20080255207A1 (en) 5-Thioxo-1,5-Dihydro-2H-Pyrrol-2-One Derivatives As Liver X Receptor Modulators
US20100016321A1 (en) Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulator
US20090029945A2 (en) Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
US20080139616A1 (en) Non-Anilinic Derivatives Of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
CN101098861A (en) Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480019841.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172760

Country of ref document: IL

Ref document number: 2004255999

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6132/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12006500071

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2532056

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006/00222

Country of ref document: ZA

Ref document number: 544622

Country of ref document: NZ

Ref document number: PA/a/2006/000414

Country of ref document: MX

Ref document number: 200600222

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006520138

Country of ref document: JP

Ref document number: 1020067000712

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004255999

Country of ref document: AU

Date of ref document: 20040708

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004255999

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004749150

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 06008249

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006102130

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004749150

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067000712

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006235015

Country of ref document: US

Ref document number: 10564235

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0412472

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10564235

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004255999

Country of ref document: AU